Bioceres Crop Solutions Corp. Acquires full Ownership of HB4® Soy and Strategic Intellectual Property Rights for Wheat

Bioceres Crop Solutions Corp. Acquires full Ownership of HB4® Soy and Strategic Intellectual Property Rights for Wheat

ROSARIO, Argentina–(BUSINESS WIRE)–Bioceres Crop Solutions Corp. (“Bioceres” or the “Company”) (NYSE American: BIOX), a fully-integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, announced today that it has entered into definitive agreements for the acquisition of the remaining 50% ownership interest in Verdeca LLC (“Verdeca”) as well as strategic Intellectual Property assets related to soybean and wheat from Arcadia Biosciences Inc. (“Arcadia”) (NASDAQ: RKDA).

OVERVIEW OF TRANSACTION

  • Bioceres has acquired from Arcadia the remaining ownership interest in Verdeca, a joint venture formed by the two companies in 2012 to develop second generation biotechnologies for soybean and to globally commercialize HB4 Soy technology. Having assumed full control of HB4 Soy, Bioceres plans to further accelerate the commercialization of this technology by increasing the number of related breeding collaborations and go-to-market partnerships in current as well as new geographies. Full ownership also enables the Company to capture significantly more of HB4 Soy’s underlying economic value as revenues from this technology are generated. As part of the transaction, Bioceres has also gained full access and control of Verdeca´s vetted soybean library of gene-edited materials used to develop new quality and productivity, as well as exclusive rights to all Arcadia technologies that are applicable to soybean.
  • Through this transaction Bioceres has also acquired rights to Arcadia’s quality wheat traits and the related Good Wheat™ brand for Latin America. The complementary portfolio of genome-edited materials being licensed includes wheat varieties that produce flour with 65% less gluten, ten times the dietary fiber content of conventional wheat flours, and oxidative stability, which extends the shelf life of whole flours and food products produced with these flours. Further, from the standpoint of consumers, these flours produce breads and other foods that are substantially equivalent in taste and all other aspects to conventional wheat. It should be noted that some of the rights being acquired by Bioceres are subject to clearances by third parties.
  • In consideration for the acquisition of the above-mentioned rights and assets, Bioceres will pay Arcadia at the closing of the transaction $5 million in cash and $15 million in equity consisting of 1,875,000 Bioceres common shares priced at $8 and which are subject to a six-month lock-up period. Bioceres has relied on the exemption from the registration requirements of the Securities Act of 1933 under Section 4(a)(2) thereof, for a transaction by an issuer not involving any public offering. One-third of these shares are pledged in favor of Bioceres and will be released to Arcadia when the aforementioned third-party clearances related to the in-licensing of the wheat rights have been granted. Following the closing of the transaction, Bioceres will also pay Arcadia: i) $2 million subject to Verdeca obtaining Chinese import clearance for HB4 Soy or achieving penetration of this technology in a minimum number of planted hectares, ii) royalty payments equivalent to 6% of the net HB4 Soy technology revenues realized by Verdeca and capped to a maximum $10 million aggregate amount of royalty payments, and iii) a royalty payment equivalent to 25% of the net wheat technology revenues resulting from the in-licensed materials. These payments do not include $1 million due to Arcadia post-closing as a reimbursement of costs associated to the transaction.

Note

Further details of the transaction will be discussed on Bioceres’ Fiscal First Quarter 2021 earnings conference call and webcast, which will be held at 8:30 a.m. EST on November 12, 2020. To access the conference call and webcast (click here).

About Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp. (NYSE American: BIOX) is a fully integrated provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The Company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation crop nutrition and protection solutions. Through its HB4® program, the Company is bringing digital solutions to support growers’ decisions and provide end-to-end traceability for production outputs. For more information, visit https://investors.biocerescrops.com

Forward-looking statements

This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial information and, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses by governments, clients and the Company, on our business, financial condition, liquidity position and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. These forward-looking statements include, but are not limited to, whether (i) the health and safety measures implemented to safeguard employees and assure business continuity will be successful, (ii) the uncertainty related to COVID-19 in the farming community will be short lived, and (iii) we will be able to coordinate efforts to ramp up inventories. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the Company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the Company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the Company’s ability to achieve its strategic goals, including the uncertainties relating to the impact of COVID-19 on the Company’s business, operations, liquidity and financial results and the other factors that are described in the sections entitled “Risk Factors” in the Company’s Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the Company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law.

Investor Relations Contact

Máximo Goya, Investor Relations

+54-341-4861100

[email protected]

KEYWORDS: Argentina South America

INDUSTRY KEYWORDS: Biotechnology Agriculture Natural Resources Health Other Natural Resources

MEDIA:

Logo
Logo

Karora Announces Record Quarterly Adjusted EBITDA of $23 Million and Record Low AISC of US$1,044 per ounce Since HGO Acquisition

Canada NewsWire


Karora will host a call/webcast on November 12, 2020 at 10:00 a.m. (Eastern Time) to discuss the third quarter results. North American callers please dial: 1-888-231-8191, international callers please dial: (+1) 647-427-7450. For the



webcast of this event click [here]



 (replay access information below).

TORONTO, Nov. 12, 2020 /CNW/ – Karora Resources Inc. (TSX: KRR) (“Karora” or the “Corporation”) is pleased to announce its financial results and review of activities for the three and nine months ended September 30, 2020. All amounts are expressed in Canadian dollars, unless otherwise noted. For additional information please refer to Karora’s Management’s Discussion & Analysis (“MD&A”) and unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2020 and 2019.

Highlights

  • Third quarter 2020 consolidated gold production was 24,717 ounces. During the first nine months of 2020 gold production was 73,612 ounces, or 80% of the mid-point of annual guidance of 90,000 to 95,000 ounces, which is maintained (assuming no significant interruption in operations as a result of the COVID-19 virus)
  • Third quarter gold sales of 22,912 ounces were 1,805 ounces lower than ounces produced due to timing of sales which is expected to be captured in the fourth quarter
  • Record low consolidated all-in-sustaining-costs (“AISC”)1 of US$1,044 per ounce since acquiring the Higginsville mill. AISC continued to trend lower despite unfavourable foreign exchange impacts compared to the second quarter which accounted for an additional US$84 per ounce due to an 8% swing in the AUD:USD exchange rate
  • Karora maintains its 2020 cost guidance of US$1,050US$1,200 per ounce and continues to target AISC costs of approximately US$1,000 per ounce by the end of 2020
  • Net earnings of $34.9 million, or $0.24 per share for the third quarter of 2020, up $25.1 million from $9.8 million in the second quarter of 2020
  • Record adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”)1 of $23.1 million or $0.16 per share for the third quarter of 2020, up $5.8 million from $17.3 million in the second quarter of 2020
  • Significantly strengthened cash position and balance sheet: Karora ended the third quarter of 2020 with a strong cash position of $67.3 million, an improvement of $17.1 million from June 30, 2020, and working capital was flat at $43.7 million
  • In the third quarter of 2020 the Corporation’s Beta Hunt mine reversed an impairment on its mineral property of $36.1 million based on an impairment assessment conducted in the third quarter of 2020. The after tax amount was $25.3 million. The initial impairment was recognized in the fourth quarter of 2017.
  • Announced new high grade gold discoveries (Larkin Gold Zone, new Footwall Zone in Western Flanks North) and first new nickel discovery in 13 years (30C Nickel Trough) at the Beta Hunt Mine. The discoveries are in close proximity to existing mine infrastructure
  • New coarse gold occurrence: On November 2, 2020, Karora announced that underground development at the Beta Hunt Mine intersected an estimated 2,000 ounces of coarse gold. The coarse gold was found in the same geological environment as previously announced coarse gold occurrences and proximal to the 2018 Father’s Day Vein discovery
  • Increased Exploration Budget: As a result of drilling success year to date and the multiple high quality exploration targets across the Western Australian operations, the 2020 exploration budget was increased by approximately 50% to A$15 million from the previous A$9.5A$10 million budget, with the majority to be spent on HGO drill targets
  • Spargos Reward acquisition completed on August 7, 2020: Spargos Reward is a high-grade open pit gold project in Western Australia that is expected to begin generating positive cash flow for Karora in 2021
  • Royalty reductions: An agreement to reduce the Beta Hunt gold royalty by 2.75% (from 7.5% to 4.75%) effective July 1, 2020 was completed on September 3, 2020. During the second quarter of 2020 the Corporation eliminated the Morgan Stanley Capital Group Inc. (“Morgan Stanley”) NSR (“Net smelter royalty”) gold royalty on the Higginsville properties. The 110,000 ounce participation payment arrangement with Morgan Stanley remains in place.
  • On November 9, 2020, Karora completed a re-purchase of the 3% gross gold royalty held by Ramelius Resources Limited in respect of the Spargos Reward Gold Project (acquired by Karora in August 2020) via payment of A$3 million, satisfied with A$2 million in cash and 264,187 Karora Shares.
  • Sale of remaining interest in Dumont Nickel Project: on July 27, 2020, Karora closed the sale of its 28% interest in the Dumont Nickel Project for proceeds of up to $47.6 million. Karora immediately received $10.7 million in cash, comprised of $7.4 million from Waterton for its interest and a $3.3 million refund of Karora’s share of the cash held within the Dumont Joint Venture. On a future sale or other monetization event, the Corporation will be entitled to receive 15% of the net proceeds from the transaction (net of certain agreed costs and deductions) up to a maximum of an additional US$30 million.
  • Effective July 31, 2020, the Corporation completed a consolidation of its outstanding common shares on the basis of one (1) post-consolidation common share for every four point five (4.5) pre-consolidation common shares. The exercise price and the number of common shares issuable under any of the Corporation’s outstanding share-based securities such as warrants, stock options and restricted share units, as applicable, have been proportionately adjusted.
  1. Non-IFRS: the definition and reconciliation of these measures are included in the Non-IFRS Measures section 14 of Karora’s MD&A dated November 12, 2020.

Paul Andre Huet, Chairman & CEO, commented: “I am very pleased with our strong operational and financial performance for the third quarter. We continued to deliver operationally robust gold production and continued our trend of reducing costs, despite challenges associated with COVID-19 and the impact of a stronger Australian dollar during the quarter, which negatively affected our US dollar cost reporting. The negative foreign exchange impact added approximately US$78 per ounce and US$84 per ounce to our cash operating costs and AISC, respectively.

Our record adjusted EBITDA of over $23 million demonstrates our cash generating power now that we have full exposure to market gold prices and significantly reduced royalties across our properties in a strong gold price environment.

We have established a strong track record over the last five quarters with our consistent production results and declining costs since we acquired the Higginsville mine and mill in 2019. During the third quarter, we produced 24,717 ounces, for total production during the first nine months of 2020 of 73,612 ounces, representing 82% of the lower end of our 2020 guidance. We did sell 1,805 fewer ounces than we produced due to the timing of sales which we expect to make up in the fourth quarter.

Our downward trend in AISC continued despite the elevated costs associated with important COVID-19 precautions we have in place at our operations and a stronger Australian dollar. AISC of US$1,044 per ounce sold during the quarter was a US$21 per ounce improvement over the second quarter of 2020 and we continue to target reaching our goal of US$1,000 per ounce by the end of 2020.

Following the 50% increase in our 2020 drilling budget to A$15 million announced in September, we are well underway with an aggressive campaign of approximately 50,000 metres to be completed in the fourth quarter. We are beginning to see some impressive results already, including three new discoveries at our Beta Hunt Mine, made up of a gold discovery in a footwall zone in the Western Flanks shear and the new Larkin Gold Zone and 30C Nickel Trough in the interpreted southern extension of the Western Flanks shear. Additionally, an ore drive in the A Zone shear recently intersected an estimated 2,000 ounces of coarse gold in the same geological environment as the Father’s Day Vein discovery. At Higginsville we recently announced positive near surface drilling results at our Aquarius Project which could potentially lead to an economic starter pit, offsetting costs associated with accessing higher grade material underground.

By the end of the year, we expect to provide an updated resource and reserve estimate for our Australian operations that will incorporate this year’s drilling as well as reflect the improved economics of our deposits given our work in reducing royalties across the portfolio.

With Karora’s record cash balance of over $67 million, our consistent gold production with full exposure to market gold prices and an aggressive drill program ongoing, I believe we are well positioned for a very exciting fourth quarter. We have built a solid platform from which we are well positioned to grow the business to the next level as we prioritize our numerous organic growth opportunities.”

COVID-19 Preparedness

Karora’s strict COVID-19 control measures at its operations remain in effect. The measures are in place to ensure operating sites remain as prepared and responsive to the situation as possible. While the situation in Western Australia with respect to COVID-19 continues to be stable, Karora continues to actively monitor the advice of local health authorities and has continued to employ a full-time nurse and supporting medical staff to monitor the status of individuals entering and leaving site. Furthermore, the Corporation’s adjusted rotations for personnel on site, use of chartered Karora-only flights where prudent, remain in place to help ensure the health and safety of its employees and stakeholders, which remains the Corporation’s top priority.

Results of Operations

Table 1 – Highlights of operational results for the periods ended September 30, 2020 and 2019

Three months ended,

Nine months ended,

For the periods ended September 30,


2020

2019


2020

2019


Gold Operations (Consolidated)

Tonnes milled (000s)


354

296


994

435

Recoveries


92%

92%


92%

92%

Gold milled, grade (g/t Au)


2.36

2.76


2.49

2.90

Gold produced (ounces)


24,717

24,216


73,612

37,403

Gold sold (ounces)


22,912

22,010


70,723

36,867

Average realized price (US $/ounce sold)


$1,905

$1,339


$1,665

$1,308

Cash operating costs (US $/ounce sold)1


$972

$1,032


$957

$1,062

All-in sustaining cost (AISC) (US $/ounce sold)1


$1,044

$1,159


$1,071

$1,173


Gold (Beta Hunt Mine)
1

Tonnes milled (000s)


191

210


563

342

Gold milled, grade (g/t Au)


2.75

2.93


2.95

3.07

Gold produced(ounces)


15,525

18,460


49,514

31,352

Gold sold (ounces)


14,502

16,593


47,603

31,155

Cash operating cost (US $/ounce sold)1


$1,035

$1,148


$985

$1,065


Gold (HGO Mine)

Tonnes milled (000s)


163

86


413

93

Gold milled grade (g/t Au)


1.91

2.34


1.88

2.27

Gold produced (ounces)


9,192

5,756


24,098

6,051

Gold sold (ounces)


8,410

5,417


23,120

5,712

Cash operating cost (US $/ounce sold)1


$863

$678


$901

$1,048

1.

Non-IFRS: the definition and reconciliation of these measures are included in the Non-IFRS Measures section 14 of Karora’s MD&A dated November 12, 2020.

Higginsville (“HGO”)

During the third quarter of 2020, 200 kt was mined and 163 kt of HGO material was milled at a grade of 1.91 g/t for production of 9,192 ounces of gold. Cash costs for the quarter were US$863 per ounce.

Production from the Baloo open pit contributed 128 kt in the quarter. A re-optimization of the pit was completed and additional mineralization identified in the northern portion of the pit which has driven the development of a new ramp from the south. Further exploration drilling will be conducted during the fourth quarter to test the eastern margins of the main mineralized zone. Drilling during the third quarter at Baloo was limited to grade control holes.

At Hidden Secret, a staged pre-stripping program to access the near surface mineralization commenced in August 2020. At Mousehollow, an open pit optimization has been completed and a mining proposal submitted to the appropriate authorities. Mining approval is expected in the fourth quarter of 2020. Once online, these combined pits will provide Karora with additional operational flexibility and mill feed optimization in addition to existing production from Baloo and Fairplay North.

Beta Hunt

During the third quarter of 2020, 191 kt of Beta Hunt material was milled at a grade of 2.75 g/t for production of 15,525 ounces of gold. Mined production from Beta Hunt was 199 kt during the quarter, a 16% increase compared to the prior quarter. The ramp up in production is a direct reflection of improved mining techniques and the addition of a CAT R2900 underground loader into the mining fleet.

Nickel production at Beta Hunt is currently restricted to remnant nickel resources south of the Alpha Fault, however, recent drilling has identified a number of new areas including the 30C Nickel Trough, where production can potentially be increased. A revised nickel production strategy, which is expected to provide a by-product credit towards gold production costs, will be based on an updated nickel mineral resource, which is expected to be completed in the fourth quarter of 2020.

Subsequent to the end of the third quarter, as announced on November 2, 2020, underground development at the Beta Hunt Mine intersected an estimated 2,000 ounces of coarse gold. The coarse gold occurrence was found in the same geological environment as previously announced coarse gold occurrences and proximal to the 2018 Father’s Day Vein discovery. The new gold occurrence provides further support of Karora’s existing Coarse Gold Geological Model at Beta Hunt which could potentially apply to other areas in the mine.

Consolidated Milling

On a consolidated basis, 354 kt were milled in the third quarter of 2020 at an average gold grade of 2.36 g/t, to produce a total of 24,717 ounces of gold, increases of 9%, 4% and 3%, respectively over the prior quarter. Milling operations had another quarter of very strong cost performance with processing costs of A$21 per tonne which was in line with the second quarter and a marked improvement compared to A$27 per tonne in the first quarter of 2020. For the third quarter, the HGO mill feed was approximately 54% Beta Hunt material and approximately 46% HGO open pit material.

Overall, Western Australia’s operational performance met or exceeded targets throughout the quarter despite the additional cost and business disruption associated with the COVID-19 pandemic which included both restricted access to certain equipment and higher cost skilled labour experienced across the State of Western Australia.

Cash Operating Costs and AISC

Cash operating costs1 and AISC1 were US$972 and US$1,044 per ounce sold respectively on a consolidated basis for the third quarter of 2020.

During the third quarter the US dollar weakened by approximately 8% against the Australian dollar when compared to the second quarter. This negatively impacted US dollar cash operating costs and all-in sustaining costs for the third quarter by approximately US$78 per ounce and US$84 per ounce, respectively. Despite this, cash operating costs1 were only 4% higher compared to the second quarter and AISC1 was 2% lower compared to the second quarter.

Outlook and New Regional Mining Strategy

Following a strong operating performance over the first three quarters of 2020 with total gold production of 73,612 ounces at an AISC1 of US$1,071 per ounce, Karora is maintaining its consolidated production and cost guidance for its Australian operations (Beta Hunt and HGO) of 90,000 to 95,000 ounces of gold at an average AISC1 of US$1,050 to US$1,200 per ounce sold. Karora continues to target AISC1 costs of approximately US$1,000 per ounce sold by the end of 2020.

As announced on November 9, 2020, a new regional mining strategy aimed at optimizing mine-to-mill feed is being developed for Karora’s 1.4 Mtpa HGO treatment plant. With the increasing number of current and planned production sources from Higginsville, Beta Hunt and Spargos, all competing for a share of the feedstock, the new strategy divides Karora’s regional operating and near-term mining areas into four main mining centres:

  1. Higginsville Central – This area is the main focus for resource definition and conversion of resources to reserve drilling and includes multiple existing and potential future open pits and underground mines (including the Aquarius deposit) contained within an approximate 10 kilometre radius of the HGO treatment plant. 
  2. Higginsville Greater – This area covers all remaining projects and deposits outside Higginsville Central. However, given its vast tenement area and large number of existing and potential resource targets, this area may be further sub-divided over time. Deposits such as Baloo and the Lake Cowan prospects fall within Higginsville Greater.
  3. Beta Hunt – The Beta Hunt underground mine.
  4. Spargos – Acquired in August 2020 and a potential source of short term, high grade mill feed to HGO.

Karora will provide further details on the new regional mining strategy following the updated resource and reserve estimate expected later in the fourth quarter.

HGO Exploration

At Aquarius, a successful near surface drilling program completed during the third quarter outlined the potential for an economic starter pit which could offset costs associated with accessing the higher grade material underground. The near surface drilling identified high grade supergene gold mineralization, including 43.5 g/t over 3.0 metres and 5.7 g/t over 6.0 metres (which included 14.6 g/t over 2.0 metres). For further details on the results, see Karora news release dated November 9, 2020. Development of the Aquarius starter pit could commence as early as mid-2021.

The existing Aquarius historical mineral resource 2 3 is 20 kt @ 19.5 g/t (Measured and Indicated) and 43 kt @ 4.2g/t (Inferred).

Beyond Aquarius, limited exploration drilling was undertaken during the third quarter at HGO owing to the utilization of the drill rigs primarily for infill and grade control drilling at Baloo, Fairplay North, Hidden Secret and Mousehollow. Exploration drilling is scheduled to ramp up in the fourth quarter of 2020 with the mobilization of additional drill rigs. Figure 1 below shows some of the areas where Karora is either actively advancing or evaluating high-priority exploration targets at HGO during the fourth quarter following the announcement in September of an expanded 2020 exploration budget to A$15 million.

_________________________________


1 Non-IFRS: the definition and reconciliation of these measures are included in the Non-IFRS Measures section 14 of Karora’s MD&A dated November 12, 2020.


2 Karora Resources profile at www.sedar.com technical report, February 6, 2020.


3 Westgold 2018 Annual Update of Mineral Resources & Ore Reserves dated October 2, 2018, available to view on the ASX (www.asx.com.au). A qualified person has not done sufficient work on behalf of Karora to classify the historical estimate noted as current mineral resources and Karora in not treating the historical estimates as current mineral resources.

Beta Hunt Exploration

Drilling at Beta Hunt during the third quarter was focused on upgrading and extending the northern margin of the Western Flanks mineral resource and testing nickel trough targets on the basalt/ultramafic contact south of the Alpha Island Fault. The drilling was successful in discovering new footwall mineralization associated with the Western Flanks mineral resource, while the nickel targeted drilling made the first new nickel discovery in 13 years (30C Nickel Trough) and, concurrently, also delineated a new gold system – the Larkin Gold Zone – directly below the 30C Nickel Trough. Please see Karora’s news releases dated September 8 and 10, 2020 for further details on the strong new discoveries made at Beta Hunt.

Exploration and resource definition drilling in the fourth quarter is directed at testing the northern, up-plunge extent of the A Zone, from both underground and surface positions, extending the southern margin of Western Flanks, testing additional nickel targets south of the Alpha Island Fault and testing the potential along strike and down-dip potential of the newly discovered Larkin Gold Zone.

Results from drilling completed will be incorporated into an updated Beta Hunt Mineral Resource and Reserve statement aimed to be released in later in the fourth quarter.

Spargos Reward Gold Project

The Spargos Reward acquisition was completed on August 7, 2020. Spargos is a historic high-grade open pit and underground gold project located approximately 50 kilometres north of Higginsville.

Karora recently negotiated the acquisition and elimination of a 3% gold royalty covering the Spargos Reward tenement for consideration of A$3 million, satisfied with A$2 million in cash and 264,187 common shares of the Corporation. Much like the elimination of the Morgan Stanley NSR previously negotiated at Higginsville, the Corporation anticipates that this will both further improve the expected strong pit economics, as well as drive further exploration successes across the Spargos land package.

An infill and extensional drilling program to convert historical mineral resources to mineral reserves is underway. A revised resource and reserve statement is expected to be completed in the fourth quarter and will form the basis of an initial mine plan. The Corporation expects to begin mining activities at Spargos in the second quarter 2021.

Financial Highlights

Table 2 – Highlights of Third Quarter Financial Results
(in thousands of dollars except per share amounts)

For the periods ended

September 30, 2020


Three months ended,

Nine months ended,


2020

2019


2020

2019

Revenue


59,405

43,092


169,787

71,204

Production and processing costs


28,032

26,670


81,093

47,212

Earnings (loss) before income taxes1


50,208

(1,557)


68,334

(17,482)

Net earnings (loss)1


34,867

(1,378)


45,224

(17,407)

Net earnings (loss) per share – basic


0.24

(0.01)


0.33

(0.15)

Net earnings (loss) per share – diluted


0.24

(0.01)


0.32

(0.15)

Adjusted EBITDA2,3


23,097

4,021


55,901

(2,758)

Adjusted EBITDA per share – basic2,3


0.16

0.03


0.41

(0.02)

Cash flow provided by (used in) operating activities


20,827

2,072


54,125

(5,942)

Cash investment in property, plant and equipment and mineral property interests


(32,333)

(4,221)


(50,558)

(17,615)

1.

For 2020, Earnings (loss) before income tax include an impairment reversal of $36.1 million and net earnings include an after tax impairment reversal of $25.3 million.

2.

Non-IFRS: the definition and reconciliation of these measures are included in the Non-IFRS Measures section of Karora’s MD&A dated November 12, 2020.

3.

Earnings before interest, taxes, depreciation, and amortization (“EBITDA”).

During the third quarter, Karora reversed an impairment on its Beta Hunt mineral property totaling $36.1 million based on an impairment assessment conducted during the quarter. After tax, the amount totaled $25.3 million based on the Australian corporate tax rate of 30%. The initial impairment was originally recognized in the fourth quarter of 2017.

Record adjusted EBITDA of $23.1 million was up 47% over the second quarter (and by $21.4 million over the corresponding 2019 period). Consolidated gold sales were 1,805 ounces less than gold produced during the third quarter (22,912 ounce sold versus 24,717 ounces produced) due to the timing of deliveries to the Perth Mint. The Corporation expects to sell these ounces during the fourth quarter.

Table 3 – Highlights of Karora’s Financial Position
(in thousands of dollars):

For the period ended


September 30, 2020

December 31, 2019

Cash and cash equivalents


67,299

34,656

Working capital1


43,739

26,506

PP&E & MPI


223,046

98,955

Total assets


315,849

177,777

Total liabilities


158,640

85,495

Shareholders’ equity


157,209

92,282

1

Working capital is a measure of current assets (including cash and cash equivalents) less current liabilities.

Karora finished the third quarter of 2020 with a strong cash position of $67.3 million, an increase of $17.1 million compared to June 30, 2020. As at September 30, 2020, Karora had a working capital surplus of $43.7 million.

For a complete discussion of financial results, please refer to Karora’s MD&A and unaudited condensed interim financial statements for the three and nine months ended September 30, 2020 and 2019.

Conference Call / Webcast

Karora will be hosting a conference call and webcast today beginning at 10:00 a.m. (Eastern time). A copy of the accompanying presentation can be found on Karora’s website at www.karoraresources.com.

Live Conference Call and Webcast Access Information:

North American callers please dial: 1-888-231-8191
Local and international callers please dial: 647-427-7450

A live webcast of the call will be available through Cision’s website at:
Webcast Link
(https://produceredition.webcasts.com/starthere.jsp?ei=1394286&tp_key=363b46ced6)

A recording of the conference call will be available for replay through the webcast link, or for a one-week period beginning at approximately 1:00 p.m. (Eastern Time) on November 12, 2020, through the following dial in numbers:

North American callers please dial: 1-855-859-2056; Pass Code: 6191855
Local and international callers please dial: 416-849-0833; Pass Code: 6191855

Compliance Statement (JORC 2012 and NI 43-101)

The disclosure of scientific and technical information contained in this news release has been reviewed and approved by Stephen Devlin, FAusIMM, Group Geologist, Karora Resources Inc., a Qualified Person for the purposes of NI 43-101.

About Karora Resources

Karora is focused on growing gold production and reducing costs at its integrated Beta Hunt Gold Mine and Higginsville Gold Operations (“HGO”) in Western Australia. The Higginsville treatment facility is a low-cost 1.4 Mtpa processing plant which is fed at capacity from Karora’s underground Beta Hunt mine and open pit Higginsville mine. At Beta Hunt, a robust gold mineral resource and reserve is hosted in multiple gold shears, with gold intersections along a 4 km strike length remaining open in multiple directions. HGO has a substantial historical gold resource and prospective land package totaling approximately 1,800 square kilometers. Karora has a strong Board and management team focused on delivering shareholder value. Karora’s common shares trade on the TSX under the symbol KRR. Karora shares also trade on the OTCQX market under the symbol KRRGF.


Cautionary Statement Concerning Forward-Looking Statements

This news release contains “forward-looking information” including without limitation statements relating to the liquidity and capital resources of Karora, production guidance and the potential of the Beta Hunt Mine, Higginsville Gold Operation, the Aquarius Project and the Spargos Gold Project.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Karora to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could affect the outcome include, among others: future prices and the supply of metals; the results of drilling; inability to raise the money necessary to incur the expenditures required to retain and advance the properties; environmental liabilities (known and unknown); general business, economic, competitive, political and social uncertainties; results of exploration programs; accidents, labour disputes and other risks of the mining industry; political instability, terrorism, insurrection or war; or delays in obtaining governmental approvals, projected cash operating costs, failure to obtain regulatory or shareholder approvals. For a more detailed discussion of such risks and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, refer to Karora ‘s filings with Canadian securities regulators, including the most recent Annual Information Form, available on SEDAR at www.sedar.com.

Although Karora has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are made as of the date of this news release and Karora disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

Cautionary Statement Regarding the Higginsville Mining Operations

A production decision at the Higginsville gold operations was made by previous operators of the mine, prior to the completion of the acquisition of the Higginsville gold operations by Karora and Karora made a decision to continue production subsequent to the acquisition. This decision by Karora to continue production and, to the knowledge of Karora, the prior production decision were not based on a feasibility study of mineral reserves, demonstrating economic and technical viability, and, as a result, there may be an increased uncertainty of achieving any particular level of recovery of minerals or the cost of such recovery, which include increased risks associated with developing a commercially mineable deposit. Historically, such projects have a much higher risk of economic and technical failure. There is no guarantee that anticipated production costs will be achieved. Failure to achieve the anticipated production costs would have a material adverse impact on the Corporation’s cash flow and future profitability. Readers are cautioned that there is increased uncertainty and higher risk of economic and technical failure associated with such production decisions.

SOURCE Karora Resources Inc.

Rupert Resources Drills 4.3g/t Gold Over 158m From 152m, 3.9g/t Gold Over 141m From 239m and 7.5g/t Gold Over 52m at Ikkari

Rupert Resources Drills 4.3g/t Gold Over 158m From 152m, 3.9g/t Gold Over 141m From 239m and 7.5g/t Gold Over 52m at Ikkari

TORONTO–(BUSINESS WIRE)–
Rupert Resources Ltd (TSX-V: RUP) (“Rupert” or “the Company”) reports new drill results of a further six holes from its ongoing exploration programme at the Ikkari discovery – part of the 100% owned Pahtavaara Project in the Central Lapland Greenstone Belt, Finland.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201112005584/en/

Figure 1. Location of new discoveries and base of till anomalies at Area 1 (Graphic: Business Wire)

Figure 1. Location of new discoveries and base of till anomalies at Area 1 (Graphic: Business Wire)

The Company has confirmed extension to 290m depth of the central part of the Ikkari discovery (as identified to date) as well as demonstrating further broad zones of mineralisation in the east, with continuity of grade in these broad zones of mineralisation persisting towards surface, above previously reported results. Furthermore, multiple very high-grade mineralised gold zones have been identified.

Highlights

  • Hole 120086 intersected 8.6g/t over 9m from 115m (89m vertical) and4.3g/t gold over 158m from 152m (115m vertical) including 11.1g/t gold over 11.4m*. 17 individual assays are greater than 10.0g/t gold. The hole targeted near-surface mineralisation above previously reported hole 120061 and confirms high-grade mineralisation over thick widths towards surface
  • Hole 120094 intersected 3.9g/t gold over 141m from 239m (182m vertical) including 9.8g/t gold over 24m from 355m* (274m vertical) which is the deepest intercept to date and demonstrates high-grade continuity to this depth
  • Hole 120089 intersected 6.4g/t gold over 63m from 134m (121m vertical) including 7.5g/t over 52m from 147m*and is a scissor hole to 120086, again confirming grade continuity across a broad zone in an eastern section of the 550m strike length. The hole also intersected a further 65m grading 2.8g/tfrom 244m
  • Hole 120059extension intersected 3.1g/t Au over 68m from 273m (220m vertical) including 6.2g/t over 16m* further confirming a broad mineralised zone above previously reported hole 120071, which demonstrates thickness of the mineralised zone on this section (figure 3b)

    * highlights only – see tables 3 and 4 for details

James Withall, CEO of Rupert Resources commented “We continue to expand the mineralised envelope and the extremely high-grade results today over good widths at the eastern extent of the drilled strike of 550m demonstrate the robust nature of the Ikkari mineralising system. The higher-grade component at Ikkari is now shown to persist to at least 290m vertical. Drilling continues to test further step-outs at depth and to the east.”

Summary

Ikkari is located in Area 1, a 5km long highly prospective section of a regional domain-bounding structure (figure 1), 20km of which is contained within Rupert’s contiguous land holding. Table 1 summarises the headline assay results to date from this discovery. As the drilling has progressed, both the scale and grade of intercepts has continued to increase. Full results of the intersections in hole 120086, from the eastern most section released to date, are included in Table 4 of this release.

Table 1. Headline assay results from Ikkari

Hole ID

Date reported

From (m)

To (m)

Interval (m)

Grade Au g/t

120094

12 November 2020

239.0

380.0

141.0

3.9

120089

136.0

199.0

63.0

6.4

120086

152.0

310.0

158.0

4.3

120084

98.0

126.0

28.0

5.4

120059*

273.0

341.0

68.0

3.1

120082

21 October 2020

91.0

279.0

188.0

3.0

120081

13.3

120.0

106.7

4.4

120080

21.5

200.0

178.5

2.0

120076

77.0

121.0

44.0

4.4

120075

17.0

198.0

181.0

3.6

120074B

01 October 2020

184.0

249.3

65.3

3.6

120071

213.0

380.0

167.0

4.2

120072

14 September 2020

9.1

210.0

200.9

1.5

120070

70.4

214.0

143.6

2.1

120069

19.8

191.0

171.2

3.0

120067

20 August 2020

10.1

182.5 (EOH)

172.4

1.3

120066

14.8

86.0

71.2

2.0

120066

166.0

296.5 (EOH)

130.5

1.2

120065

53.0

84.0

31.0

2.1

120061

29 June 2020

167.0

191.0

24.0

0.9

120061

212.0

233.0

21.0

1.2

120061

273.0

320.0

47.0

4.1

120059

121.0

134.0

13.0

15.2

120042

12 May 2020

10.8

148.0

137.2

1.8

120038

25.0

79.0

54.0

1.5

Notes to table: No upper cut-off grade and a 0.4g/t Au lower cut-off applied. Unless specified, true widths cannot be accurately determined from the information available. Full breakdown of new holes with “includings” in Table 3. Refer to previous releases at https://rupertresources.com/news/ for details of previously released drilling intercepts. EOH – End of Hole. * Drilling extension to previously drilled and previously reported hole

Ongoing drilling at the Ikkari discovery has further demonstrated the continuity of a broad mineralised envelope across at least 550m of strike length (figure 2). In addition, these new results demonstrate some of the very high-grade mineralisation contained within the discovery. Hole 120094 (figure 3a) is a good example, with an intercept of 9.8g/t gold over 24m (as part of a broader mineralised envelope of 3.9g/t gold over 141m) commencing 262m below surface and 140m approximately vertically below the overlying intercept in hole 120080, that included intervals such as 7.3g/t gold over 15m. This high-grade zone is localised at the contact between albitised felsic sediments and altered mafic-ultramafic rocks, with broader mineralisation persisting throughout both the felsic sediment and mafic-ultramafic units, as seen in several previously reported drill holes from Ikkari.

Further drilling on the same section as previously reported hole 120061 (figure 3c), which intersected 4.1g/t Au over 47m, demonstrates broad zones of mineralisation towards surface (120086 – 4.3g/t Au over 158m and 120084 – 5.4g/t Au over 28m). The potential broad thickness of this zone is supported by scissor hole 120089 (6.4g/t Au over 63m). Also in hole 120089 a second zone of mineralisation at depth (2.8g/t Au over 65m) intersects with hole 120061 to confirm further significant mineralised thickness at 280m depth. This section is structurally complex, with narrow sediment units dismembered and displaced within the host rock package.

The mineralisation at Ikkari remains open in all directions. Drilling continues to progress, targeting depth extensions and systematically stepping out along the predicted strike indicated by base of till anomalies, which extends for more than 1 km in total (figure 2). To date, 14,356 metres have been drilled at Ikkari in 50 holes, with results reported for 31 holes.

Table 2. Collar locations of new Ikkari target drill holes

Hole ID

Easting

Northing

Elevation

Azimuth

Dip

EOH (m)

120094

454133.3

7496681.6

225.6

332.2

-50.0

567.0

120089

454167.3

7496993.0

223.0

156.2

-65.4

414.2

120086

454254.2

7496805.2

225.0

332.6

-50.3

419.1

120085

454346.9

7496979.6

223.9

335.8

-50.0

80.6

120084

454227.0

7496858.3

224.4

335.2

-50.5

295.6

120059

454215.2

7496772.7

225.3

327.8

-49.9

397.7**

Notes to table: The coordinates are in ETRS89 Z35 and all holes are surveyed at 3m intervals downhole and all core is orientated. ** Previously reported with EOH at 247.5m depth (29/06/2020) before hole was extended to current depth.

Mineralisation Description

Mineralisation at Ikkari is characterised by intense alteration and deformation. Gold is associated with fine-grained disseminated pyrite within planar quartz-carbonate veins and / or disseminated in the host rocks, commonly as fine-grained visible gold. Host rocks observed thus far include sedimentary rocks overprinted by albite-sericite alteration, and strongly foliated chlorite-altered mafic-ultramafic rocks. A broader, variably mineralised alteration zone comprising magnetite ± hematite ± tourmaline ± K-feldspar ± fuchsite is also present. Holes demonstrate strong foliation, shearing, and veining that is predominantly parallel to the dominant structural fabric and gold appears to be concentrated in sedimentary intercalations associated with zones of structural disruption at lithological boundaries, represented by irregular, cross-cutting vein associations and brittle fracture in albite-altered rocks. The regional structural data collected so far suggest a subvertical, broad and linear structure, within which cross-cutting fractures and variably dipping lithologies, as well as possibly folded bedding, appear to have controlled the introduction of gold-bearing fluids and associated alteration zones. In general, alteration and structure appear to be sub-vertical, with lithologies dipping ~70 degrees north.

About the Pahtavaara Project

The Pahtavaara Project is located in the heart of the Central Lapland Greenstone Belt, Northern Finland where the company owns the permitted Pahtavaara mine that is on active care & maintenance and within a contiguous licence package of some 325km2. The Company acquired the project for just USD $2.5m in 2016 and is undertaking exploration both at the existing mine and across the region to demonstrate the potential for significant economic mineralisation.

Area 1 comprises a large part of a structural corridor that lies between Kittilä Group allochthon to the north and the younger Kumpu Group basin to the south. The zone is dominated by large E-W to ENE trending faults which have controlled broad to isoclinal folding within the sediment-dominated (Savukoski Group) rock package. A complex network of cross cutting structures has focused multi-stage fluid flow, with gold mineralisation associated with massive to fine-grained disseminated sulphides and concentrated at favourable structural intersections.

Review by Qualified Person, Quality Control and Reports

Mr. Mike Sutton, P.Geo. Director and Dr Charlotte Seabrook, MAIG, RPGeo. Exploration Manager are the Qualified Persons as defined by National Instrument 43-101 responsible for the accuracy of scientific and technical information in this news release.

Samples are prepared by ALS Finland in Sodankylä and assayed in ALS laboratories in Ireland, Romania or Sweden. All samples are under watch from the drill site to the storage facility. Samples are assayed using fire assay method with aqua regia digest and analysis by AAS for gold. Over limit analysis for >10 ppm Au is conducted using fire assay and gravimetric finish for assays over >100ppm Au. For hole 120071 all mineralised samples were submitted for screen fire assays with gravimetric finish. For multi-element assays Ultra Trace Level Method by HF-HNO3-HClO4 acid digestion, HCl leach and a combination of ICP-MS and ICP-AES is used. The Company’s QA/QC program includes the regular insertion of blanks and standards into the sample shipments, as well as instructions for duplication. Standards, blanks and duplicates are inserted at appropriate intervals. Approximately five percent (5%) of the pulps and rejects are sent for check assaying at a second lab.

Base of till samples are prepared in ALS Sodankylä by dry-sieving method prep-41, and assayed by fire assay with ICP-AES finish for gold. Multi-elements are assayed in ALS laboratories in either of Ireland, Romania or Sweden by aqua regia with ICP-MS finish. Rupert maintains a strict chain of custody procedure to manage the handling of all samples. The Company’s QA/QC program includes the regular insertion of blanks and standards into the sample shipments, as well as instructions for duplication.

– Ends –

About Rupert

Rupert is a Canadian based gold exploration and development company that is listed on the TSX Venture Exchange under the symbol “RUP”. The Company owns the Pahtavaara gold mine, mill, and exploration permits and concessions located in the Central Lapland Greenstone Belt in Northern Finland (“Pahtavaara”). Pahtavaara previously produced over 420koz of gold and 474koz remains in an Inferred mineral resource (4.6 Mt at a grade of 3.2 g/t Au at a 1.5 g/t Au cut-off grade, see the technical report entitled “NI 43-101 Technical Report: Pahtavaara Project, Finland” with an effective date of April 16, 2018, prepared by Brian Wolfe, Principal Consultant, International Resource Solutions Pty Ltd., an independent qualified person under National Instrument 43-101 – Standards of Disclosure for Mineral Projects). The Company also holds a 100% interest in the Surf Inlet Property in British Columbia, a 100% interest in properties in Central Finland; and a 20% carried participating interest in the Gold Centre property located adjacent to the Red Lake mine in Ontario.

Web: http://rupertresources.com/

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward Looking Statements

This press release contains statements which, other than statements of historical fact constitute “forward-looking statements” within the meaning of applicable securities laws, including statements with respect to: results of exploration activities, mineral resources. The words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions, as they relate to the Company, are intended to identify such forward-looking statements. Investors are cautioned that forward-looking statements are based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made, and are inherently subject to a variety of risks and uncertainties and other known and unknown factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. These factors include the general risks of the mining industry, as well as those risk factors discussed or referred to in the Company’s annual Management’s Discussion and Analysis for the year ended February 29, 2020 available at www.sedar.com. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements except as otherwise required by applicable law.

APPENDIX

Table 3. New Intercepts at Ikkari

Hole ID

 

From (m)

To (m)

Interval (m)

Grade Au (g/t)

120094

 

28.0

32.0

3.5

3.0

 

 

239.0

380.0

141.0

3.9

 

Including

285.0

286.0

1.0

7.0

 

Including

297.0

298.0

1.0

40.2

 

Including

313.0

314.0

1.0

10.7

 

Including

346.0

349.0

3.0

48.5

 

And including

347.0

348.0

1.0

115.0

 

Including

355.0

379.0

24.0

9.8

 

And including

355.0

356.0

1.0

30.2

 

 

431.0

434.0

3.0

1.3

120089

 

114.0

117.0

3.0

0.9

 

 

136.0

199.0

63.0

6.4

 

Including

147.0

199.0

52.0

7.5

 

Including

148.0

153.0

5.0

10.3

 

Including

159.0

169.0

6.0

19.3

 

Including

181.0

182.0

1.0

48.3

 

Including

186.0

187.0

1.0

16.2

 

Including

189.0

190.0

1.0

16.8

 

Including

197.0

199.0

2.0

14.1

 

 

244.0

309.0

65.0

2.8

 

Including

256.0

270.0

14.0

5.5

 

Including

284.0

287.0

3.0

16.9

 

And including

286.0

287.0

1.0

33.9

 

Including

307.0

308.0

1.0

9.1

 

 

320.0

322.0

2.0

1.7

 

 

396.0

397.0

1.0

1.8

120086

 

44.0

45.0

3.0

1.5

 

 

116.0

125.0

9.0

8.6

 

Including

118.0

119.0

1.0

42.7

 

 

130.0

131.0

1.0

5.3

 

 

152.0

310.0

158.0

4.3

 

Including

159.6

171.0

11.4

11.1

 

And including

164.0

165.0

1.0

46.6

 

Including

176.0

177.0

1.0

8.3

 

Including

199.0

201.0

2.0

21.0

 

Including

210.0

211.0

1.0

7.8

 

Including

228.0

241.0

13.0

9.7

 

And including

239.0

240.0

1.0

34.0

 

Including

252.0

254.0

2.0

9.0

 

Including

268.0

275.0

7.0

17.0

 

And including

273.0

274.0

1.0

38.7

 

Including

294.0

295.0

1.0

15.1

 

 

322.0

323.0

1.0

30.0

 

 

330.0

331.0

2.0

5.6

 

 

364.0

365.0

1.0

1.6

 

 

380.0

381.0

1.0

2.1

 

 

407.0

412.0

5.0

1.0

 

Table 3. New Intercepts at Ikkari (continued)

Hole ID

 

From (m)

To (m)

Interval (m)

Grade Au g/t

120084

 

98.0

126.0

28.0

5.4

 

Including

105.0

106.0

1.0

20.0

 

 

113.0

115.0

2.0

37.1

 

 

209.0

212.0

3.0

3.3

120059

 

273.0

341.0

68.0

3.1

(Extension*)

Including

273.0

274.0

1.0

28.4

 

Including

292.0

308.0

16.0

6.2

 

And including

307.0

308.0

1.0

17.2

 

 

320.0

321.0

1.0

7.9

 

 

336.6

337.0

0.4

10.2

 

No upper cut-off grade and a 0.4g/t Au lower cut-off applied. Unless specified, true widths cannot be accurately determined from the information available. Bold intervals referred to in text of release. Refer to https://rupertresources.com/news/ for details of previously released drilling intercepts. * Hole 120059 reported previously (June 30, 2020) with only results from the extension reported here.

Table 4. Complete assay table of drill hole 120086 from 115m to EOH

From (m)

To (m)

Interval (m)

Grade Au (g/t)

115.0

115.5

0.5

0.0

115.5

116.0

0.5

0.3

116.0

117.0

1.0

2.1

117.0

118.0

1.0

9.5

118.0

119.0

1.0

42.7

119.0

120.0

1.0

10.6

120.0

121.0

1.0

0.5

121.0

122.0

1.0

8.2

122.0

123.0

1.0

2.5

123.0

124.0

1.0

2.1

124.0

125.0

1.0

1.7

125.0

126.0

1.0

0.4

126.0

127.0

1.0

0.0

127.0

128.0

1.0

0.1

128.0

129.0

1.0

0.1

129.0

130.0

1.0

0.1

130.0

131.0

1.0

5.3

131.0

132.0

1.0

0.0

132.0

133.0

1.0

0.0

133.0

134.0

1.0

0.0

134.0

135.0

1.0

0.0

135.0

136.0

1.0

0.0

136.0

137.0

1.0

0.0

137.0

138.0

1.0

0.3

138.0

139.0

1.0

0.0

139.0

140.0

1.0

0.0

140.0

141.0

1.0

0.0

141.0

142.0

1.0

0.0

142.0

143.0

1.0

0.0

143.0

144.0

1.0

0.0

144.0

145.0

1.0

0.0

145.0

146.0

1.0

0.0

146.0

147.0

1.0

0.0

147.0

148.0

1.0

0.0

148.0

149.0

1.0

0.1

149.0

150.0

1.0

0.0

150.0

151.0

1.0

0.0

151.0

152.0

1.0

0.0

152.0

153.0

1.0

4.2

153.0

154.0

1.0

0.5

154.0

155.0

1.0

0.1

155.0

156.0

1.0

0.1

156.0

157.0

1.0

1.0

157.0

158.0

1.0

1.4

158.0

159.0

1.0

0.5

159.0

159.6

0.6

2.7

159.6

160.0

0.4

7.6

 

 

 

 

From (m)

To (m)

Interval (m)

Grade Au (g/t)

160.0

161.0

1.0

6.0

161.0

162.0

1.0

2.1

162.0

163.0

1.0

2.5

163.0

164.0

1.0

15.3

164.0

165.0

1.0

46.6

165.0

166.0

1.0

8.5

166.0

167.0

1.0

5.8

167.0

168.0

1.0

8.4

168.0

169.0

1.0

7.5

169.0

170.0

1.0

1.6

170.0

171.0

1.0

19.2

171.0

172.0

1.0

2.6

172.0

173.0

1.0

2.0

173.0

174.0

1.0

0.8

174.0

175.0

1.0

1.5

175.0

176.0

1.0

3.8

176.0

177.0

1.0

8.3

177.0

178.0

1.0

4.2

178.0

179.0

1.0

0.6

179.0

180.0

1.0

0.2

180.0

181.0

1.0

0.0

181.0

182.0

1.0

0.1

182.0

183.0

1.0

0.1

183.0

184.0

1.0

0.1

184.0

185.0

1.0

0.2

185.0

186.0

1.0

0.2

186.0

187.0

1.0

0.9

187.0

188.0

1.0

0.1

188.0

189.0

1.0

1.4

189.0

189.8

0.8

4.4

189.8

191.0

1.2

2.2

191.0

192.0

1.0

0.7

192.0

193.0

1.0

1.4

193.0

194.0

1.0

4.7

194.0

195.0

1.0

4.4

195.0

196.0

1.0

3.8

196.0

197.0

1.0

0.9

197.0

198.0

1.0

0.3

198.0

199.0

1.0

0.5

199.0

200.0

1.0

13.1

200.0

201.0

1.0

28.9

201.0

202.0

1.0

0.2

202.0

203.0

1.0

1.3

203.0

204.0

1.0

2.2

204.0

205.0

1.0

2.2

205.0

206.0

1.0

1.4

206.0

207.0

1.0

1.1

 

Table 4. Complete assay table of drill hole 120086 from 115m to EOH

From (m)

To (m)

Interval (m)

Grade Au (g/t)

207.0

208.0

1.0

0.4

208.0

209.0

1.0

1.2

209.0

210.0

1.0

1.4

210.0

211.0

1.0

7.8

211.0

212.0

1.0

2.6

212.0

213.0

1.0

3.7

213.0

214.0

1.0

2.8

214.0

215.0

1.0

0.0

215.0

216.0

1.0

0.0

216.0

217.0

1.0

0.0

217.0

218.0

1.0

0.1

218.0

219.0

1.0

0.5

219.0

220.0

1.0

0.1

220.0

221.0

1.0

0.4

221.0

222.0

1.0

0.1

222.0

223.0

1.0

2.4

223.0

224.0

1.0

0.5

224.0

225.0

1.0

3.6

225.0

226.0

1.0

1.8

226.0

227.0

1.0

5.0

227.0

228.0

1.0

0.5

228.0

229.0

1.0

16.5

229.0

230.0

1.0

0.0

230.0

231.0

1.0

0.1

231.0

232.0

1.0

7.8

232.0

233.0

1.0

13.3

233.0

234.0

1.0

13.5

234.0

235.0

1.0

20.9

235.0

236.0

1.0

1.8

236.0

237.0

1.0

3.3

237.0

238.0

1.0

0.2

238.0

239.0

1.0

1.0

239.0

240.0

1.0

34.0

240.0

241.0

1.0

13.6

241.0

242.0

1.0

4.7

242.0

243.0

1.0

2.0

243.0

244.0

1.0

0.4

244.0

245.0

1.0

5.0

245.0

246.0

1.0

1.7

246.0

247.0

1.0

4.6

247.0

248.0

1.0

0.9

248.0

249.0

1.0

1.1

249.0

250.0

1.0

1.2

250.0

251.0

1.0

2.3

251.0

252.0

1.0

1.1

252.0

253.0

1.0

7.0

253.0

254.0

1.0

11.1

 

 

 

 

From (m)

To (m)

Interval (m)

Grade Au (g/t)

254.0

255.0

1.0

0.8

255.0

256.0

1.0

0.0

256.0

257.0

1.0

0.3

257.0

258.0

1.0

2.8

258.0

259.0

1.0

4.0

259.0

260.0

1.0

5.8

260.0

261.0

1.0

1.5

261.0

262.0

1.0

4.0

262.0

263.0

1.0

0.4

263.0

264.0

1.0

1.2

264.0

265.0

1.0

1.9

265.0

266.0

1.0

4.4

266.0

267.0

1.0

5.2

267.0

268.0

1.0

1.3

268.0

269.0

1.0

24.4

269.0

270.0

1.0

7.4

270.0

271.0

1.0

18.5

271.0

272.0

1.0

2.2

272.0

273.0

1.0

10.4

273.0

274.0

1.0

38.7

274.0

275.0

1.0

17.3

275.0

276.0

1.0

1.0

276.0

277.0

1.0

3.5

277.0

278.0

1.0

5.4

278.0

279.0

1.0

4.5

279.0

280.0

1.0

1.5

280.0

281.0

1.0

1.2

281.0

282.0

1.0

2.6

282.0

283.0

1.0

3.3

283.0

284.0

1.0

7.7

284.0

285.0

1.0

1.9

285.0

286.0

1.0

1.7

286.0

287.0

1.0

0.7

287.0

288.0

1.0

0.5

288.0

289.0

1.0

2.8

289.0

289.4

0.4

1.8

289.4

290.0

0.6

1.6

290.0

291.0

1.0

1.0

291.0

292.0

1.0

2.4

292.0

293.0

1.0

2.0

293.0

294.0

1.0

4.2

294.0

295.0

1.0

15.1

295.0

296.0

1.0

5.2

296.0

297.0

1.0

2.1

297.0

298.0

1.0

1.9

298.0

299.0

1.0

2.4

299.0

300.0

1.0

5.0

 

Table 4. Complete assay table of drill hole 120086 from 115m to EOH

From (m)

To (m)

Interval (m)

Grade Au (g/t)

300.0

301.0

1.0

0.3

301.0

302.0

1.0

1.5

302.0

303.0

1.0

0.1

303.0

304.0

1.0

2.9

304.0

305.0

1.0

0.6

305.0

306.0

1.0

0.0

306.0

307.0

1.0

0.0

307.0

308.0

1.0

0.1

308.0

309.0

1.0

0.5

309.0

310.0

1.0

2.6

310.0

311.0

1.0

0.4

311.0

312.0

1.0

0.0

312.0

313.0

1.0

0.0

313.0

314.0

1.0

0.0

314.0

315.0

1.0

0.1

315.0

316.0

1.0

0.0

316.0

317.0

1.0

0.1

317.0

318.0

1.0

0.0

318.0

319.0

1.0

0.0

319.0

320.0

1.0

0.0

320.0

321.0

1.0

0.0

321.0

322.0

1.0

0.1

322.0

322.5

0.5

54.5

322.5

323.0

0.5

5.5

323.0

324.0

1.0

0.0

324.0

325.0

1.0

0.0

325.0

326.0

1.0

0.0

326.0

327.0

1.0

0.0

327.0

328.0

1.0

0.0

328.0

329.0

1.0

0.0

329.0

330.0

1.0

0.0

330.0

331.0

1.0

8.4

331.0

332.0

1.0

2.8

332.0

333.0

1.0

0.1

333.0

334.0

1.0

0.1

334.0

335.0

1.0

0.0

335.0

336.0

1.0

0.2

336.0

337.0

1.0

0.0

337.0

338.0

1.0

0.0

338.0

339.0

1.0

0.0

339.0

340.0

1.0

0.0

340.0

341.0

1.0

0.0

341.0

342.0

1.0

0.0

342.0

343.0

1.0

0.0

343.0

344.0

1.0

0.0

344.0

345.0

1.0

0.0

345.0

346.0

1.0

0.0

 

 

 

 

From (m)

To (m)

Interval (m)

Grade Au (g/t)

346.0

347.0

1.0

0.0

347.0

348.0

1.0

0.0

348.0

349.0

1.0

0.0

349.0

350.0

1.0

0.0

350.0

351.0

1.0

0.0

351.0

352.0

1.0

0.0

352.0

353.0

1.0

0.1

353.0

354.0

1.0

0.2

354.0

355.0

1.0

0.2

355.0

356.0

1.0

0.1

356.0

357.0

1.0

0.0

357.0

358.0

1.0

0.0

358.0

359.0

1.0

0.0

359.0

360.0

1.0

0.0

360.0

361.0

1.0

0.0

361.0

362.0

1.0

0.0

362.0

363.0

1.0

0.0

363.0

364.0

1.0

0.1

364.0

365.0

1.0

1.6

365.0

366.0

1.0

0.1

366.0

367.0

1.0

0.4

367.0

368.0

1.0

0.0

368.0

369.0

1.0

0.0

369.0

370.0

1.0

0.0

370.0

371.0

1.0

0.0

371.0

372.0

1.0

0.8

372.0

373.0

1.0

0.0

373.0

374.0

1.0

0.0

374.0

375.0

1.0

0.1

375.0

376.0

1.0

0.1

376.0

377.0

1.0

0.0

377.0

378.0

1.0

0.0

378.0

379.0

1.0

0.1

379.0

380.0

1.0

0.2

380.0

381.0

1.0

2.1

381.0

382.0

1.0

0.0

382.0

383.0

1.0

0.0

383.0

384.0

1.0

0.0

384.0

385.0

1.0

0.2

385.0

386.0

1.0

0.1

386.0

387.0

1.0

0.0

387.0

388.0

1.0

0.1

388.0

389.0

1.0

0.0

389.0

390.0

1.0

0.0

390.0

391.0

1.0

0.2

391.0

392.0

1.0

0.0

392.0

393.0

1.0

0.0

 

Table 4. Complete assay table of drill hole 120086 from 115m to EOH

From (m)

To (m)

Interval (m)

Grade Au (g/t)

393.0

394.0

1.0

0.0

394.0

395.0

1.0

0.0

395.0

396.0

1.0

0.0

396.0

397.0

1.0

0.0

397.0

398.0

1.0

0.0

398.0

399.0

1.0

0.0

399.0

400.0

1.0

0.0

400.0

401.0

1.0

0.0

401.0

402.0

1.0

0.0

402.0

403.0

1.0

0.0

403.0

404.0

1.0

0.0

404.0

405.0

1.0

0.0

405.0

406.0

1.0

0.3

406.0

407.0

1.0

0.1

407.0

408.0

1.0

1.0

408.0

409.0

1.0

1.1

409.0

410.0

1.0

1.0

410.0

411.0

1.0

1.3

411.0

412.0

1.0

0.8

412.0

413.0

1.0

0.1

413.0

414.0

1.0

0.0

414.0

415.0

1.0

0.3

415.0

416.0

1.0

0.2

416.0

417.0

1.0

0.0

417.0

418.0

1.0

0.0

418.0

419.1

1.1

0.2

 

 

For further information, please contact:

James Withall

Chief Executive Officer

[email protected]

Thomas Credland

Head of Corporate Development

[email protected]

Rupert Resources Ltd

82 Richmond Street East, Suite 203, Toronto, Ontario M5C 1P1

Tel: +1 416-304-9004

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Mining/Minerals Natural Resources

MEDIA:

Photo
Photo
Figure 3b. Simplified geology cross section B – B’ showing location of new intercepts (Graphic: Business Wire)
Photo
Photo
Figure 3c. Simplified geology cross section C – C’ showing location of new intercepts (Graphic: Business Wire)
Photo
Photo
Figure 3a. Simplified geology cross section A – A’ showing location of new intercepts (Graphic: Business Wire)
Photo
Photo
Figure 2. Location of new drilling results at the Ikkari target (Graphic: Business Wire)
Photo
Photo
Figure 1. Location of new discoveries and base of till anomalies at Area 1 (Graphic: Business Wire)

Unum Group Announces Leadership Transition for Unum International Business

PR Newswire

CHATTANOOGA, Tenn., Nov. 12, 2020 /PRNewswire/ — Unum (NYSE: UNM) today announced that Mark Till will oversee Unum International’s business as Executive Vice President. Mr. Till will join Unum on February 1, 2021, and will be officially appointed to the role on April 1, 2021, subject to regulatory approval. Peter O’Donnell will be transitioning from his role as Executive Vice President of Unum International, but will remain with Unum through the first quarter of 2021 to ensure a seamless transition. Mr. O’Donnell has decided to make this change in order to pursue a portfolio career and has been an integral part of the hiring process for Mr. Till.

“Unum is pleased to welcome Mark Till, who we are confident will continue to build upon the momentum that Peter has established for Unum’s business in Europe,” said Unum President & Chief Executive Officer, Rick McKenney. “Peter has been an instrumental part of Unum for the past decade and will truly be missed. He has kept our company focused on unmatched customer service and has grown our business into the trusted brand it is today in both the UK and Poland. I want to thank Peter for his dedication and wish him the best in his future endeavors.”

“It has been a privilege over the past ten years to work at Unum and have the support of our great people across the organization,” said Mr. O’Donnell. “I’m proud of what we have accomplished to support our customers and grow the business. While this was a difficult decision, I am confident in the future direction of the business and that I’m leaving Unum International in great hands.”

“I’m excited to join the great team at Unum International and build off Peter’s many accomplishments,” said Mr. Till. “Helping the working world thrive has never been more important, and I’m confident we can continue to advance the customer experience and grow Unum’s International’s business in the region.”

Mr. Till has served Aegon as Managing Director, Platform Solutions, responsible for all aspects of the Aegon UK business revenue and proposition for intermediaries and their customers. Additionally, Mr. Till previously served as Head of Personal Investing & UK Marketing Director for Fidelity International, where he managed over 275,000 customers and £12 billion of customer investments. Mr. Till has also held positions with Standard Life, HomeServe PLC and Barclays Bank.

Mr. O’Donnell joined Unum’s UK subsidiary, Unum Limited, in June 2010 as the Chief Financial Officer. He has served as Chief Executive Officer of Unum’s UK business since September 2012, and as Executive Vice President of Unum International since October 2018. Mr. O’Donnell has also served as a member of Unum Limited’s Board of Directors. During his time with Unum, Mr. O’Donnell made significant contributions to the growth of Unum’s brand in the UK and oversaw Unum’s expansion into Poland.

Unum International is comprised of both Unum UK and Unum Poland and serves as the European arm of Unum Group. Unum UK is the leading provider of group income protection and critical illness coverage in the United Kingdom, as well as a provider of life and dental benefits. Additionally, Unum Poland has been providing group and individual life insurance in the Polish market for more than twenty years. Following the acquisition of Unum Poland in 2018, both companies fell under the Unum International business unit.

About Unum
Unum Group (www.unum.com) provides a broad portfolio of financial protection benefits and services through the workplace and is a leading provider of disability income protection worldwide. Through its Unum US, Unum UK, Unum Poland, and Colonial Life businesses, the company provides disability, life, accident, critical illness, dental and vision benefits that protect millions of working people and their families.  Unum also provides leave and absence management services that streamline the leave experience for employers and employees and stop-loss coverage to help self-insured employers protect against medical costs.  Unum reported revenues of $12.0 billion in 2019 and provided $7.5 billion in benefits. 

For more information, connect with us on Facebook, Twitter and LinkedIn.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/unum-group-announces-leadership-transition-for-unum-international-business-301171860.html

SOURCE Unum Group

Fortune Minerals Announces Successful Completion of NICO Geophysical Program and Identification of IOCG Targets

Fortune Minerals Announces Successful Completion of NICO Geophysical Program and Identification of IOCG Targets

Aurora Geosciences retained to prepare more detailed interpretation report with drill targets

LONDON, Ontario–(BUSINESS WIRE)–Fortune Minerals Limited (TSX: FT) (OTCQB: FTMDF) (“Fortune” or the “Company”) (www.fortuneminerals.com) is pleased to report that Aurora Geosciences Ltd. (“Aurora”) has completed the previously announced induced polarization (“I.P.”) and ground magnetometer geophysical surveys along the projected east extension of the NICO Gold-Cobalt-Bismuth-Copper Deposit (“NICO Deposit”) in Canada’s Northwest Territories. The surveys were successful in outlining several large areas of coincident chargeability and magnetic high response with low electrical resistivity indicative of near-surface magnetic and conductive sources. Fortune has retained Aurora to complete a more detailed interpretation of the survey results with three-dimensional (“3-D”) modelling of the combined anomalies based on the property geology and the Company’s historical geophysical and LiDar databases. The report deliverables will include recommendations for drill testing of the identified anomalies with specified collar locations and targeting information.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201112005579/en/

Fortune Minerals Limited Apparent Resistivity Map (Photo: Business Wire)

Fortune Minerals Limited Apparent Resistivity Map (Photo: Business Wire)

Like our news? Click-to-Tweet.

Aurora completed the ground magnetometer and I.P. surveys on the NICO property in late September and a field report was delivered at the end of October. The results include a kilometer-long area of coincident magnetic, chargeability and resistivity anomalies extending southeast from the presently defined east end of the NICO Deposit. This is an area where there are block faults with vertical and horizontal displacement of the geology. Only limited drilling was carried out in this in this area, but a hole completed in 1997 intersected 3 metres, grading 1.1 grams of per tonne (“g/t”) gold. The geophysics and drill-hole data indicate the east end of the NICO Deposit may be open for possible expansion.

The previously disclosed Peanut Lake anomaly (see Fortune news release, dated September 2, 2020) was also delineated by Aurora with partly overlapping magnetic, chargeability and resistivity anomalies ranging from 400 to 600 metres wide. These anomalies coincide with gravity and magnetic anomalies identified in earlier geophysical surveys for Fortune as well as 3-D inversion modelling of a combined magnetic, gravity and magnetotelluric anomaly by the Geological Survey of Canada. Three holes drilled in this area in 1997 also intersected mineralization similar to the NICO Deposit with grades of 1.11 g/t gold and 0.355% cobalt, 1.16 g/t gold and 0.06% cobalt, 1.52 g/t gold and 0.05% cobalt – each over 3 metre core lengths. The Peanut Lake anomaly aligns with the southeast fault projected extension of the NICO Deposit stratigraphy. The geophysical results and the aforesaid drill intersections, located 800 metres southeast of the currently defined east terminus of the deposit, indicate that the deposit may continue in this direction.

The Aurora geophysical surveys also identified a new area of previously unrecognized combined magnetic and chargeability high anomalies with corresponding low resistivity located approximately 200 metres northeast of the east end of the NICO Deposit. The anomalies extend 700 metres east to NICO Lake where they remain open for possible expansion beneath the water. Additional smaller anomalies were also discovered in the surveys.

The NICO Deposit is an IOCG-type ore deposit with age and geological features common to very large global analogues, including the ‘super giant’ Olympic Dam mine in South Australia, and support the blue-sky exploration potential. NICO is uniquely positioned as one of the few advanced cobalt development assets globally with Proven and Probable Open Pit and Underground Mineral Reserves totaling 33 million tonnes containing 1.1 million ounces of gold, 82.3 million pounds of cobalt, 102.1 million pounds of bismuth, and 27.2 million pounds of copper. The expansion potential is important as leading western economies work to diversify their sources of critical minerals. Cobalt and bismuth are both identified by the U.S. and European Union as Critical Minerals. Critical Minerals have essential use in important manufacturing and defense industries, cannot be easily substituted by other minerals, and their supply chains are threatened by geographic concentration of production and/or geopolitical risks with the current sources of supply. Canada and the U.S. have announced a joint action plan on Critical Mineral supply to help develop more North American production of these raw materials needed to support the growth of new technologies. The NICO Deposit also stands out among other Critical Mineral and cobalt development projects with a million ounce in-situ gold co-product.

For more detailed information about the NICO Mineral Reserves and certain technical information in this news release, please refer to the Technical Report on the NICO Project, entitled “Technical Report on the Feasibility Study for the NICO-Gold-Cobalt-Bismuth-Copper Project, Northwest Territories, Canada”, dated April 2, 2014 and prepared by Micon International Limited which has been filed on SEDAR and is available under the Company’s profile at www.sedar.com. The disclosure of scientific and technical information contained in this news release has been approved by Robin Goad, M.Sc., P.Geo., President and Chief Executive Officer of Fortune who is a “Qualified Person” under National Instrument 43-101.

About Fortune Minerals:

Fortune is a Canadian mining company focused on developing the NICO Gold-Cobalt-Bismuth-Copper Project in the Northwest Territories. The Company has an option to purchase lands in Saskatchewan where it may build the hydrometallurgical plant to process NICO metal concentrates. Fortune also owns the satellite Sue-Dianne Copper-Silver-Gold Deposit located 25 km north of the NICO Project, which is a potential future source of incremental mill feed to extend the life of the NICO Project mill.

Follow Fortune Minerals:

Click here to subscribe to Fortune’s email list.

Click here to follow Fortune on LinkedIn.

@FortuneMineral on Twitter.

This press release contains forward-looking information and forward-looking statements within the meaning of applicable securities legislation. This forward-looking information includes statements with respect to, among other things, the potential for expansion of the NICO Deposit, the Company’s plans to develop the NICO Project and the potential for the Sue-Dianne property to provide incremental mill feed to the NICO Project. Forward-looking information is based on the opinions and estimates of management as well as certain assumptions at the date the information is given (including, in respect of the forward-looking information contained in this press release, assumptions regarding: the Company’s ability to secure a site in southern Canada for the construction of a NICO Project refinery; the Company’s ability to arrange the necessary financing to continue operations and develop the NICO Project; the receipt of all necessary regulatory approvals for the construction and operation of the NICO Project and the related hydrometallurgical refinery and the timing thereof; growth in the demand for cobalt; the time required to construct the NICO Project; and the economic environment in which the Company will operate in the future, including the price of gold, cobalt and other by-product metals, anticipated costs and the volumes of metals to be produced at the NICO Project). However, such forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. These factors include the risks that further exploration of the Peanut Lake anomaly may not result in a meaningful expansion of the NICO Deposit, the NICO Project may not receive the benefit of any financing under the published initiatives of the United States and European Union with respect to critical minerals or any other benefits therefrom, the Company may not be able to secure a site for the construction of a refinery, the Company may not be able to finance and develop NICO on favourable terms or at all, uncertainties with respect to the receipt or timing of required permits, approvals and agreements for the development of the NICO Project, including the related hydrometallurgical refinery, the construction of the NICO Project may take longer than anticipated, the Company may not be able to secure offtake agreements for the metals to be produced at the NICO Project, the Sue-Dianne Property may not be developed to the point where it can provide mill feed to the NICO Project, the inherent risks involved in the exploration and development of mineral properties and in the mining industry in general, the market for products that use cobalt or bismuth may not grow to the extent anticipated, the future supply of cobalt and bismuth may not be as limited as anticipated, the risk of decreases in the market prices of cobalt, bismuth and other metals to be produced by the NICO Project, discrepancies between actual and estimated Mineral Resources or between actual and estimated metallurgical recoveries, uncertainties associated with estimating Mineral Resources and Reserves and the risk that even if such Mineral Resources prove accurate the risk that such Mineral Resources may not be converted into Mineral Reserves once economic conditions are applied, the Company’s production of cobalt, bismuth and other metals may be less than anticipated and other operational and development risks, market risks and regulatory risks. Readers are cautioned to not place undue reliance on forward-looking information because it is possible that predictions, forecasts, projections and other forms of forward-looking information will not be achieved by the Company. The forward-looking information contained herein is made as of the date hereof and the Company assumes no responsibility to update or revise it to reflect new events or circumstances, except as required by law.

For further information please contact:

Fortune Minerals Limited

Troy Nazarewicz

Investor Relations Manager

[email protected]

Tel.: (519) 858-8188

www.fortuneminerals.com

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Mining/Minerals Natural Resources

MEDIA:

Logo
Logo
Photo
Photo
Fortune Minerals Limited Apparent Resistivity Map (Photo: Business Wire)

TransDigm Group Reports Fiscal 2020 Fourth Quarter Results

PR Newswire

CLEVELAND, Nov. 12, 2020 /PRNewswire/ — TransDigm Group Incorporated (NYSE: TDG), a leading global designer, producer and supplier of highly engineered aircraft components, today reported results for the fourth quarter ended September 30, 2020, which were significantly impacted by the COVID-19 pandemic.

Fourth quarter highlights include:

  • Net sales of $1,173 million, down 23.9% from $1,541 million in the prior year’s quarter;
  • Income from continuing operations of $101 million;
  • Earnings per share from continuing operations of $1.76;
  • EBITDA As Defined margin of 42.4%;
  • EBITDA As Defined of $498 million is down 29.6% from $707 million in the prior year’s quarter;
  • Adjusted earnings per share of $2.89, down 48.6% from $5.62; and
  • Strong operating cash flow generation of $222 million.

Fiscal 2020 highlights include:

  • Net sales of $5,103 million, down 2.3% from $5,223 million in the prior year;
  • Income from continuing operations of $653 million;
  • Earnings per share from continuing operations of $8.14;
  • EBITDA As Defined margin of 44.6%;
  • EBITDA As Defined of $2,278 million is down 5.8% from $2,419 million in the prior year; and
  • Adjusted earnings per share of $14.47, down 20.8% from $18.27.

Fiscal 2021 financial guidance will not be issued at this time.

Quarter-to-Date Results

Net sales for the quarter declined 23.9%, or $368 million, to $1,173 million from $1,541 million in the comparable quarter a year ago. In the current quarter, all sales represent organic sales.

Income from continuing operations for the quarter was $101 million, a decrease of 68.1% compared to $317 million in the comparable quarter a year ago. The decrease in income from continuing operations primarily reflects the decline in net sales described above. This decline in income from continuing operations was partially offset by a lower effective tax rate.

Adjusted net income for the quarter decreased 47.5% to $166 million, or $2.89 per share, from $316 million, or $5.62 per share, in the comparable quarter a year ago.

EBITDA for the quarter decreased 40.9% to $414 million from $700 million for the comparable quarter a year ago. EBITDA As Defined for the period decreased 29.6% to $498 million compared with $707 million in the comparable quarter a year ago. EBITDA As Defined as a percentage of net sales for the quarter was 42.4%.

“Throughout our fourth fiscal quarter, both passenger demand and air traffic remained depressed due to the COVID-19 pandemic. The pandemic has resulted in governments around the world implementing measures to control the spread of the virus, including quarantines, travel restrictions and other measures. Certain markets have reopened, while others, particularly international markets, remained closed or are enforcing extended quarantines. Despite these headwinds, I am pleased that we were able to sequentially expand our EBITDA As Defined margin to about forty-two and a half percent as a result of careful management of our cost structure,” stated Kevin Stein, TransDigm Group’s President and Chief Executive Officer.

Year-to-Date Results

Fiscal 2020 net sales declined 2.3%, or $120 million, to $5,103 million from $5,223 million in the comparable period last year. Organic sales declined 13.8%. Acquisition sales growth was $603 million, all of which are attributable to Esterline.  

Fiscal 2020 income from continuing operations declined 22.4% to $653 million compared to $841 million in the comparable period a year ago. This decrease in income from continuing operations primarily reflects the decline in net sales described above, along with higher interest expense, higher operating costs and amortization expense attributable to Esterline and COVID-19 restructuring costs. The decline in income from continuing operations was offset partially by lower acquisition related expenses and a lower effective tax rate. The effective tax rate for fiscal 2020 was positively impacted by a one-time provisional benefit from dividend and dividend equivalent payments made in the period, as well as the enactment of the CARES Act which included favorable modifications to the interest deduction limitation. The effective tax rate for full-year fiscal 2020 was 11.7% compared to 20.9% for fiscal 2019.

GAAP earnings per share were reduced in fiscal 2020 and 2019 by $3.22 per share and $1.97 per share, respectively, as a result of dividend and dividend equivalent payments made during each year.

Fiscal 2020 adjusted net income decreased 19.3% to $829 million, or $14.47 per share, from $1,028 million, or $18.27 per share, in the comparable period a year ago.

Fiscal 2020 EBITDA decreased 4.4% to $2,052 million from $2,148 million for the comparable period a year ago. EBITDA As Defined for the period decreased 5.8% to $2,278 million compared with $2,419 million in the comparable period a year ago. EBITDA As Defined as a percentage of net sales for the current period was 44.6%.

Mr. Stein continued, “Fiscal 2020 has been a challenging year given the unprecedented COVID-19 pandemic and ensuing disruption of the commercial aerospace industry. These circumstances required actions that were necessary, but difficult to implement. The purposeful management of our cost structure, along with tight management of our balance sheet, better positions us as a Company to emerge strongly from the ongoing weakness in our primary commercial end markets. With the recent uptick in global COVID-19 cases as well as renewed lockdowns in certain countries, much uncertainty remains about the duration of the pandemic and pace of recovery. We will continue to be focused in our management of the details and look forward to the opportunity to create value for our stakeholders in fiscal 2021.”

Please see the attached tables for a reconciliation of income from continuing operations to EBITDA, EBITDA As Defined, and adjusted net income; a reconciliation of net cash provided by operating activities to EBITDA and EBITDA As Defined, and a reconciliation of earnings per share to adjusted earnings per share for the periods discussed in this press release.

Fiscal 2021 Outlook

Given the considerable uncertainty around the extent and duration of business disruptions related to the COVID-19 pandemic, and how that will impact operations, the Company will not provide fiscal year 2021 guidance at this time.

Earnings Conference Call

TransDigm Group will host a conference call for investors and security analysts on November 12, 2020, beginning at 11:00 a.m., Eastern Time. To join the call, dial (833) 397-0943 and enter the passcode 8789968.  International callers should dial (720) 405-3217 and use the same passcode. A live audio webcast can be accessed online at http://www.transdigm.com. A slide presentation will also be available for reference during the conference call; go to the investor relations page of our website and click on “Presentations.”

The call will be archived on the website and available for replay at approximately 2:00 p.m., Eastern Time. A telephone replay will be available for one week by dialing (855) 859-2056 and entering the passcode 8789968. International callers should dial (404) 537-3406 and use the same passcode.

About TransDigm Group

TransDigm Group, through its wholly-owned subsidiaries, is a leading global designer, producer and supplier of highly engineered aircraft components for use on nearly all commercial and military aircraft in service today. Major product offerings, substantially all of which are ultimately provided to end-users in the aerospace industry, include mechanical/electro-mechanical actuators and controls, ignition systems and engine technology, specialized pumps and valves, power conditioning devices, specialized AC/DC electric motors and generators, batteries and chargers, engineered latching and locking devices, engineered rods, engineered connectors and elastomer sealing solutions, databus and power controls, cockpit security components and systems, specialized and advanced cockpit displays, aircraft audio systems, specialized lavatory components, seat belts and safety restraints, engineered and customized interior surfaces and related components, advanced sensor products, switches and relay panels, thermal protection and insulation, lighting and control technology, parachutes, high performance hoists, winches and lifting devices, and cargo loading, handling and delivery systems.

Non-GAAP Supplemental Information

EBITDA, EBITDA As Defined, EBITDA As Defined Margin, adjusted net income and adjusted earnings per share are non-GAAP financial measures presented in this press release as supplemental disclosures to net income and reported results. TransDigm Group defines EBITDA as earnings before interest, taxes, depreciation and amortization and defines EBITDA As Defined as EBITDA plus certain non-operating items, refinancing costs, acquisition-related costs, transaction-related costs and non-cash charges incurred in connection with certain employee benefit plans. TransDigm Group defines adjusted net income as net income plus purchase accounting backlog amortization expense, effects from the sale on businesses, refinancing costs, acquisition-related costs, transaction-related costs and non-cash charges incurred in connection with certain employee benefit plans. EBITDA As Defined Margin represents EBITDA As Defined as a percentage of net sales. TransDigm Group defines adjusted diluted earnings per share as adjusted net income divided by the total shares for basic and diluted earnings per share. For more information regarding the computation of EBITDA, EBITDA As Defined and adjusted net income and adjusted earnings per share, please see the attached financial tables.

TransDigm Group presents these non-GAAP financial measures because it believes that they are useful indicators of its operating performance. TransDigm Group believes that EBITDA is useful to investors because it is frequently used by securities analysts, investors and other interested parties to measure operating performance among companies with different capital structures, effective tax rates and tax attributes, capitalized asset values and employee compensation structures, all of which can vary substantially from company to company. In addition, analysts, rating agencies and others use EBITDA to evaluate a company’s ability to incur and service debt. EBITDA As Defined is used to measure TransDigm Inc.’s compliance with the financial covenant contained in its credit facility. TransDigm Group’s management also uses EBITDA As Defined to review and assess its operating performance, to prepare its annual budget and financial projections and to review and evaluate its management team in connection with employee incentive programs. Moreover, TransDigm Group’s management uses EBITDA As Defined to evaluate acquisitions and as a liquidity measure. In addition, TransDigm Group’s management uses adjusted net income as a measure of comparable operating performance between time periods and among companies as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance.

None of EBITDA, EBITDA As Defined, EBITDA As Defined Margin, adjusted net income or adjusted earnings per share is a measurement of financial performance under GAAP and such financial measures should not be considered as an alternative to net income, operating income, earnings per share, cash flows from operating activities or other measures of performance determined in accordance with GAAP. In addition, TransDigm Group’s calculation of these non-GAAP financial measures may not be comparable to the calculation of similarly titled measures reported by other companies.

Although we use EBITDA and EBITDA As Defined as measures to assess the performance of our business and for the other purposes set forth above, the use of these non-GAAP financial measures as analytical tools has limitations, and you should not consider any of them in isolation, or as a substitute for analysis of our results of operations as reported in accordance with GAAP. Some of these limitations are:

  • neither EBITDA nor EBITDA As Defined reflects the significant interest expense, or the cash requirements necessary to service interest payments, on our indebtedness;
  • although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and neither EBITDA nor EBITDA As Defined reflects any cash requirements for such replacements;
  • the omission of the substantial amortization expense associated with our intangible assets further limits the usefulness of EBITDA and EBITDA As Defined;
  • neither EBITDA nor EBITDA As Defined includes the payment of taxes, which is a necessary element of our operations; and
  • EBITDA As Defined excludes the cash expense we have incurred to integrate acquired businesses into our operations, which is a necessary element of certain of our acquisitions.

Forward-Looking Statements

Statements in this press release that are not historical facts, including statements under the heading “Fiscal 2021 Outlook,” are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “may,” “will,” “should,” “expect,” “intend,” “plan,” “predict,” “anticipate,” “estimate,” or “continue” and other words and terms of similar meaning may identify forward-looking statements.

All forward-looking statements involve risks and uncertainties that could cause TransDigm Group’s actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of, TransDigm Group. These risks and uncertainties include but are not limited to: the impact that the COVID-19 pandemic has on the TransDigm Group’s business, results of operations, financial condition and liquidity; the sensitivity of TransDigm Group’s business to the number of flight hours that its customers’ planes spend aloft and its customers’ profitability, both of which are affected by general economic conditions; future geopolitical or other worldwide events; cyber-security threats and natural disasters; TransDigm Group’s reliance on certain customers; the U.S. defense budget and risks associated with being a government supplier including government audits and investigations; failure to maintain government or industry approvals; failure to complete or successfully integrate acquisitions, including TransDigm Group’s acquisition of Esterline; TransDigm Group’s indebtedness; potential environmental liabilities; liabilities arising in connection with litigation; increases in raw material costs, taxes and labor costs that cannot be recovered in product pricing; risks and costs associated with TransDigm Group’s international sales and operations; and other risk factors. Further information regarding the important factors that could cause actual results to differ materially from projected results can be found in TransDigm Group’s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and other reports that TransDigm Group or its subsidiaries have filed with the Securities and Exchange Commission. Except as required by law, TransDigm Group undertakes no obligation to revise or update the forward-looking statements contained in this press release.


Contact:

Investor Relations

216-706-2945


[email protected]

 


TRANSDIGM GROUP INCORPORATED


CONDENSED CONSOLIDATED STATEMENTS OF INCOME


FOR THE THIRTEEN WEEK PERIODS AND FISCAL YEARS ENDED


Table 1


SEPTEMBER 30, 2020 AND SEPTEMBER 30, 2019


(Amounts in millions, except per share amounts)


(Unaudited)


Thirteen Week Periods Ended


Fiscal Year Ended


September 30,
2020


September 30,
2019


September 30,
2020


September 30,
2019

NET SALES

$

1,173

$

1,541

$

5,103

$

5,223

COST OF SALES

637

659

2,456

2,414

GROSS PROFIT

536

882

2,647

2,809

SELLING AND ADMINISTRATIVE EXPENSES

182

212

727

748

AMORTIZATION OF INTANGIBLE ASSETS

41

55

169

135

INCOME FROM OPERATIONS

313

615

1,751

1,926

INTEREST EXPENSE – NET

267

245

1,029

859

REFINANCING COSTS

1

28

3

OTHER (INCOME) EXPENSE

(31)

3

(46)

1

INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES

76

367

740

1,063

INCOME TAX PROVISION

(25)

50

87

222

INCOME FROM CONTINUING OPERATIONS

101

317

653

841

(LOSS) INCOME FROM DISCONTINUED OPERATIONS, NET OF TAX

(19)

31

47

51

NET INCOME

82

348

700

892

LESS: NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS

(1)

(1)

(2)

NET INCOME ATTRIBUTABLE TO TD GROUP

$

82

$

347

$

699

$

890

NET INCOME APPLICABLE TO TD GROUP COMMON STOCKHOLDERS

$

82

$

260

$

514

$

779

Earnings per share attributable to TD Group common stockholders:

Earnings per share from continuing operations – basic and diluted

$

1.76

$

4.08

$

8.14

$

12.94

(Loss) Earnings per share from discontinued operations – basic and diluted

(0.33)

0.55

0.82

0.90

Earnings per share

$

1.43

$

4.63

$

8.96

$

13.84

Cash dividends declared per common share

$

$

30.00

$

32.50

$

30.00

Weighted-average shares outstanding:

Basic and diluted

57.3

56.3

57.3

56.3

 


TRANSDIGM GROUP INCORPORATED


SUPPLEMENTAL INFORMATION – RECONCILIATION OF EBITDA,


EBITDA AS DEFINED TO INCOME FROM CONTINUING OPERATIONS


FOR THE THIRTEEN WEEK PERIODS AND FISCAL YEARS ENDED


Table 2


SEPTEMBER 30, 2020 AND SEPTEMBER 30, 2019


(Amounts in millions, except per share amounts)


(Unaudited)


Thirteen Week Periods Ended


Fiscal Year Ended


September 30,
2020


September 30,
2019


September 30,
2020


September 30,
2019

Income from continuing operations

$

101

$

317

$

653

$

841

Adjustments:

Depreciation and amortization expense

71

88

283

226

Interest expense, net

267

245

1,029

859

Income tax provision

(25)

50

87

222

EBITDA

414

700

2,052

2,148

Adjustments:

Acquisition-related expenses and adjustments (1)

13

(16)

31

169

Non-cash stock compensation expense (2)

34

23

93

93

Refinancing costs (3)

1

28

3

COVID-19 & 737 MAX restructuring costs (4)

23

54

Other, net (5)

13

20

6

Gross Adjustments to EBITDA

84

7

226

271

EBITDA As Defined

$

498

$

707

$

2,278

$

2,419

EBITDA As Defined, Margin (6)

42.4

%

45.9

%

44.6

%

46.3

%


(1)

Represents accounting adjustments to inventory associated with acquisitions of businesses and product lines that were charged to cost of sales when the inventory was sold; costs incurred to integrate acquired businesses and product lines into TD Group’s operations, facility relocation costs and other acquisition-related costs; transaction-related costs comprising deal fees; legal, financial and tax due diligence expenses; and valuation costs that are required to be expensed as incurred.


(2)

Represents the compensation expense recognized by TD Group under our stock incentive plans.


(3)

Represents costs expensed related to debt financing activities, including new issuances, extinguishments, refinancings and amendments to existing agreements.


(4)

Represents restructuring costs related to the Company’s cost reduction measures in response to the COVID-19 pandemic ($22 million and $46 million for the thirteen week period and fiscal year ended September 30, 2020, respectively) and the 737 MAX production rate changes ($3 million for the fiscal year ended September 30, 2020. None in the thirteen week period ended September 30, 2020). These were costs related to the Company’s actions to reduce its workforce to align with customer demand. This also includes $1 million and $5 million for the thirteen week period and fiscal year ended September 30, 2020, respectively, of incremental costs related to the pandemic that are not expected to recur once the pandemic has subsided and are clearly separable from normal operations (e.g., additional cleaning and disinfecting of facilities by contractors above and beyond normal requirements, personal protective equipment, etc.).


(5)

Primarily represents foreign currency transaction gains or losses, payroll withholding taxes related to special dividend and dividend equivalent payments and stock option exercises, non-service related pension costs, deferred compensation and gain or loss on sale of fixed assets.


(6)

The EBITDA As Defined margin represents the amount of EBITDA As Defined as a percentage of sales.

 


TRANSDIGM GROUP INCORPORATED


SUPPLEMENTAL INFORMATION – RECONCILIATION OF


REPORTED EARNINGS PER SHARE TO


ADJUSTED EARNINGS PER SHARE


FOR THE THIRTEEN WEEK PERIODS AND FISCAL YEARS ENDED


Table 3


SEPTEMBER 30, 2020 AND SEPTEMBER 30, 2019


(Amounts in millions, except per share amounts)


(Unaudited)


Thirteen Week Periods Ended


Fiscal Year Ended


September 30,
2020


September 30,
2019


September 30,
2020


September 30,
2019


Reported Earnings Per Share

Income from continuing operations

$

101

$

317

$

653

$

841

Less: Net income attributable to noncontrolling interests

(2)

(1)

(2)

Net income from continuing operations attributable to TD Group

101

315

652

839

Less: Special dividends declared or paid on participating securities, including dividend equivalent payments

(87)

(185)

(111)

101

228

467

728

(Loss) Income from discontinued operations, net of tax

(19)

32

47

51

Net income applicable to TD Group common stockholders – basic and diluted

$

82

$

260

$

514

$

779


Weighted-average shares outstanding under the two-class method

Weighted-average common shares outstanding

54.3

53.4

53.9

53.1

Vested options deemed participating securities

3.0

2.9

3.4

3.2

Total shares for basic and diluted earnings per share

57.3

56.3

57.3

56.3

Earnings per share from continuing operations – basic and diluted

$

1.76

$

4.08

$

8.14

$

12.94

(Loss) Earnings per share from discontinued operations – basic and diluted

(0.33)

0.55

0.82

0.90

Earnings per share

$

1.43

$

4.63

$

8.96

$

13.84


Adjusted Earnings Per Share

Income from continuing operations

$

101

$

317

$

653

$

841

Gross adjustments to EBITDA

84

7

226

271

Purchase accounting backlog amortization

12

20

53

38

Tax adjustment (1)

(31)

(28)

(103)

(122)

Adjusted net income

$

166

$

316

$

829

$

1,028

Adjusted diluted earnings per share under the two-class method

$

2.89

$

5.62

$

14.47

$

18.27


Diluted Earnings Per Share to Adjusted Earnings Per Share

Diluted earnings per share from continuing operations

$

1.76

$

4.08

$

8.14

$

12.94

Adjustments to diluted earnings per share:

   Inclusion of the dividend equivalent payments

1.54

3.22

1.97

   Acquisition-related expenses

0.42

0.05

1.20

2.77

   Non-cash stock compensation expense

0.57

0.33

1.32

1.24

   Refinancing costs

0.02

0.40

0.04

Change in income tax provision due to excess tax benefits on stock compensation

(0.48)

(0.40)

(0.89)

(0.79)

   COVID-19 & 737 MAX restructuring costs

0.39

0.76

   Other, net

0.21

0.02

0.32

0.10

Adjusted earnings per share

$

2.89

$

5.62

$

14.47

$

18.27


(1)

For the thirteen week periods and fiscal years ended September 30, 2020 and 2019, the Tax adjustment represents the tax effect of the adjustments at the applicable effective tax rate, as well as the impact on the effective tax rate when excluding the excess tax benefits on stock option exercises. Stock compensation expense is excluded from adjusted net income and therefore we have excluded the impact that the excess tax benefits on stock option exercises have on the effective tax rate for determining adjusted net income.

 


TRANSDIGM GROUP INCORPORATED


SUPPLEMENTAL INFORMATION – RECONCILIATION OF NET CASH


Table 4


PROVIDED BY OPERATING ACTIVITIES TO EBITDA,


EBITDA AS DEFINED


FOR THE FISCAL YEAR ENDED


SEPTEMBER 30, 2020 AND SEPTEMBER 30, 2019


(Amounts in millions)


(Unaudited)


Fiscal Year Ended


September 30, 2020


September 30, 2019

Net cash provided by operating activities

$

1,213

$

1,015

Adjustments:

Changes in assets and liabilities, net of effects from acquisitions of businesses

(99)

176

Interest expense, net (1)

996

831

Income tax provision – current

63

222

Non-cash stock compensation expense (2)

(93)

(93)

Refinancing costs (3)

(28)

(3)

EBITDA

2,052

2,148

Adjustments:

Acquisition-related expenses (4)

31

169

Non-cash stock compensation expense (2)

93

93

Refinancing costs (3)

28

3

COVID-19 & 737 MAX restructuring costs (5)

54

Other, net (6)

20

6

EBITDA As Defined

$

2,278

$

2,419


(1)

Represents interest expense excluding the amortization of debt issue costs and premium and discount on debt.


(2)

Represents the compensation expense recognized by TD Group under our stock incentive plans.


(3)

Represents costs expensed related to debt financing activities, including new issuances, extinguishments, refinancings and amendments to existing agreements.


(4)

Represents accounting adjustments to inventory associated with acquisitions of businesses and product lines that were charged to cost of sales when the inventory was sold; costs incurred to integrate acquired businesses and product lines into TD Group’s operations, facility relocation costs and other acquisition-related costs; transaction-related costs comprising deal fees; legal, financial and tax due diligence expenses and valuation costs that are required to be expensed as incurred.


(5)

Represents restructuring costs related to the Company’s cost reduction measures in response to the COVID-19 pandemic ($46 million) and the 737 MAX production rate changes ($3 million). These were costs related to the Company’s actions to reduce its workforce to align with customer demand. This also includes $5 million of incremental costs related to the pandemic that are not expected to recur once the pandemic has subsided and are clearly separable from normal operations (e.g., additional cleaning and disinfecting of facilities by contractors above and beyond normal requirements, personal protective equipment, etc.).


(6)

Primarily represents foreign currency transaction gain or loss, payroll withholding taxes related to special dividend and dividend equivalent payments and stock option exercises, non-service related pension costs, deferred compensation and gain or loss on sale of fixed assets.

 


TRANSDIGM GROUP INCORPORATED


SUPPLEMENTAL INFORMATION – BALANCE SHEET DATA


Table 5


(Amounts in millions)


(Unaudited)


September 30, 2020


September 30, 2019

Cash and cash equivalents

$

4,717

$

1,467

Trade accounts receivable – net

720

1,068

Inventories – net

1,283

1,233

Current portion of long-term debt

276

80

Short-term borrowings-trade receivable securitization facility

349

350

Accounts payable

218

276

Accrued current liabilities

773

675

Long-term debt

19,384

16,469

Total TD Group stockholders’ deficit

(3,972)

(2,894)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/transdigm-group-reports-fiscal-2020-fourth-quarter-results-301171489.html

SOURCE TransDigm Group Inc.

Carlyle Makes Strategic Growth Investment in Leading Ecommerce Marketplace Enablement Platform and Retail Seller Pharmapacks

PR Newswire

NEW YORK, Nov. 12, 2020 /PRNewswire/ — Pharmapacks, LLC (“Pharmapacks” or “Company”), a leading ecommerce enablement platform and retail seller for brands across major ecommerce marketplaces, today announced a strategic investment of more than $250 million from global investment firm The Carlyle Group (NASDAQ: CG) to accelerate the Company’s growth plans. The growth investment places Pharmapacks’ enterprise value at approximately $1.1 billion.

Pharmapacks was founded as a single brick and mortar pharmacy and has since evolved into a platform providing brands with best-in-class ecommerce capabilities. Since 2010, Pharmapacks has cultivated extensive partnerships with consumer brands across ecommerce marketplaces in North America, including Amazon, Walmart, eBay, Target, Google and Facebook.

Powered by its proprietary platform, Pharmapacks is trusted by millions of customers to provide for their daily needs. After reaching over $250 million in sales in 2019, Pharmapacks is on a current run rate to achieve approximately 60% year-over-year growth and, with the opening of an additional 230k square foot replenishment center this month, Pharmapacks is expected to fuel accelerated growth in Q4.

“Pharmapacks is experiencing unprecedented growth with massive market support and highly attractive industry dynamics,” said Andrew Vagenas, Chief Executive Officer of Pharmapacks. “We are thrilled that our partnership with Carlyle, a world-class investment firm with extensive connectivity, data and global resources, will provide us with an opportunity to take significant steps to enter the next phase of our growth plans.”

“We’re thrilled to partner with another founder-led growth company, leveraging the global resources of the Carlyle platform to support Pharmapacks’ acceleration,” said Jay Sammons, Carlyle’s Head of Global Consumer, Media & Retail. “We are focused on identifying companies that are growing significantly faster than the market and benefiting from strong secular tailwinds. As a company sitting at the cross section of a number of attractive trends, including the massive and rapid expansion of ecommerce, we have strong conviction in Pharmapacks’ ability to achieve sustainable growth.”

“We’re excited to partner with Andrew and the Pharmapacks management team to execute a multi-dimensional growth strategy for the Company,” said Yue Bonnet, a Principal specializing in Consumer, Media & Retail at Carlyle. “We believe there are significant opportunities to support the Company’s value creation plans by helping to rapidly increase the number of consumer brand partners, building out the data and analytics platform and increasing capacity through additional warehouse expansion.”

The investment in Pharmapacks is a continuation of Carlyle’s long-term global commitment to Consumer, Media & Retail in which it has invested more than $21.5 billion of equity since inception. Equity capital for the investment came from Carlyle Partners VII, an $18.5 billion fund that makes majority and strategic minority investments primarily in the U.S. in targeted industries, including Consumer, Media & Retail.

J.P. Morgan served as lender and advisor to the Company.

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across four business segments: Corporate Private Equity, Real Assets, Global Credit and Investment Solutions. With $230 billion of assets under management as of September 30, 2020, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. Carlyle employs more than 1,800 people in 30 offices across six continents. Further information is available at www.carlyle.com. Follow Carlyle on Twitter @OneCarlyle.

About Pharmapacks

Pharmapacks, LLC is a leading ecommerce enablement platform and retail seller for brands across major ecommerce marketplaces with proprietary technology that empowers brands with a complete and cost-effective logistics, fulfillment, marketing and sales solution. Pharmapacks has a premier team of ecommerce experts with over 10 years’ experience and 850 employees connecting consumers to their favorite brands on online marketplaces such as Amazon, Walmart, Target, Google, eBay and Facebook, becoming one of the largest marketplace sellers in North America. Pharmapacks serves as a “launch pad” for emerging brands by giving a select amount of lesser-known brands access to the Pharmapacks’ e-commerce platform and consumer base. This enables brands to focus on product research and development, while Pharmapacks strategically sets competitive price points and builds a connection between the consumer and the brand.

Media Contacts:

Brittany Berliner

[email protected]

+1 (212) 813 4839

Jeremy Watkins

[email protected]

+1 (212) 430 5050

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/carlyle-makes-strategic-growth-investment-in-leading-ecommerce-marketplace-enablement-platform-and-retail-seller-pharmapacks-301171711.html

SOURCE Pharmapacks

InMode Reports Record Third Quarter 2020 Financial Results; Quarterly Revenues of $59.7 Million Represent 49% Year over Year Growth, GAAP and *Non-GAAP Diluted Earnings per Share of $0.57 and $0.63

PR Newswire

YOKNEAM, Israel, Nov. 12, 2020 /PRNewswire/ — InMode Ltd. (Nasdaq: INMD) (“InMode”), a leading global provider of innovative medical technologies, today announced consolidated financial results for its third quarter ended September 30, 2020.

InMode Logo


Third Quarter 2020 Highlights:

  • Record quarterly revenues of $59.7 million, an increase of 49% compared to the third quarter of 2019; approximately 58% of quarterly revenues derived from InMode’s proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments, approximately 35% of quarterly revenues derived from InMode’s recently introduced hands-free platforms and approximately 7% derived from InMode’s traditional laser and non-invasive RF platforms
  • Record GAAP net income of $23.9 million, compared to $16.2 million in the third quarter of 2019; *non-GAAP net income of $26.6 million, compared to $16.5 million in the third quarter of 2019
  • Record GAAP diluted earnings per share of $0.57 compared to $0.42 in the third quarter of 2019; *non-GAAP diluted earnings per share of $0.63 compared to $0.42 in the third quarter of 2019
  • Total cash position of $234.3 million as of September 30, 2020, including cash and cash equivalents, marketable securities and short-term bank deposits

 

 


U.S. GAAP Results

(U.S. dollars in thousands, except for per share data)


         Q3 2020


Q3 2019

Revenues

$59,714

$40,010

Gross Margins

84%

87%

Net Income Attributable to InMode Ltd.

$23,895

$16,186

Earnings per Diluted Share

$0.57

$0.42


*Non-GAAP Results


(U.S. dollars in thousands, except for per share data)


         Q3 2020


Q3 2019

Gross Margins

85%

87%

Net Income Attributable to InMode Ltd.

$26,638

$16,512

Earnings per Diluted Share

$0.63

$0.42

*Please refer to “Use of Non-GAAP Financial Measures” below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation and related tax adjustments.


Management Comments

“Our record third quarter revenues were driven by the success of our minimally invasive and hands-free solutions in the United States and internationally, strengthening the leading market position of our harnessed electro-surgical technologies. The steadfast sales & marketing investments we made throughout the pandemic enabled our organization to quickly meet surging demand as restrictions loosened,” commented Moshe Mizrahy, InMode’s CEO.

“During the quarter, we continued to focus on research & development and were excited to announce the launch of the Morpheus8 Body handpiece and Morpheus8 Platform. We understand that the uncertainties of the COVID-19 pandemic are not behind us, and we will remain committed to the health of our employees and our organization,” commented Dr. Michael Kreindel, InMode’s CTO and co-founder.

“We believe the steps we took over the last several months were instrumental in building interest, increased awareness and demand for InMode technologies, which translated into record sales in the third quarter. We believe we are emerging as the standard of care for minimally invasive aesthetic surgeries, as we continue to innovate and deliver versatile offerings. We expect continued underlying demand for our differentiated products heading into the fourth quarter of 2020,” commented Shakil Lakhani, President of North America.


2020 Guidance

We expect that our revenues for the full year of 2020 will be between $192 million and $195 million, and we expect to maintain a *non-GAAP gross margin of 84%-86%.

This outlook is not a guarantee of future performance and stockholders should not rely on such forward-looking statements. See “Forward-Looking Statements” for additional information.


Third Quarter 2020 Financial Results

Total revenues for the third quarter of 2020 were $59.7 million, an increase of 49% as compared to the third quarter of 2019. The increase in revenues was driven primarily by the expansion of InMode’s direct sales organization in the United States and the continued momentum of InMode’s hands-free technology, as well as the recently introduced Morpheus8 Body fractional technology. Moreover, InMode continued to gain traction in international markets, with international revenues growing 109% year-over-year.

GAAP gross margin for the third quarter of 2020 was 84% compared to a gross margin of 87% in the third quarter of 2019. *Non-GAAP gross margin for the third quarter of 2020 was 85% compared to a gross margin of 87% in the third quarter of 2019. This decrease is primarily attributable to the increase of sales in international markets, mainly in countries where we operate through distributors.

GAAP operating margin for the third quarter of 2020 was 39%, compared to 40% in the third quarter of 2019. *Non-GAAP operating margin for the third quarter of 2020 was 43%, compared to 41% in the third quarter of 2019. This increase in *non-GAAP operating margin was primarily attributable to decreased marketing activities in the United States such as event and conference participation, due to restrictions caused by the COVID-19 pandemic.

InMode reported GAAP net income attributable to InMode Ltd. of $23.9 million, or $0.57 per diluted share in the third quarter of 2020 compared to $16.2 million, or $0.42 per diluted share, in the third quarter of 2019. On a *non-GAAP basis, InMode reported net income attributable to InMode Ltd. of $26.6 million, or $0.63 per diluted share in the third quarter of 2020 compared to $16.5 million, or $0.42 per diluted share, in the third quarter of 2019.

“We ended the third quarter with a strong balance sheet and record results. Our measured approach of investing for the future while maintaining flexibility during the COVID-19 pandemic has paid off this quarter,” noted Yair Malca, InMode’s CFO. “During the quarter, we announced a share repurchase program of up to one million of InMode’s shares, which reflects our unwavering faith in InMode’s success.”

*Please refer to “Use of Non-GAAP Financial Measures” below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation and related tax adjustments.


Use of Non-GAAP Financial Measures

In addition to InMode’s operating results presented in accordance with GAAP, this release includes certain non-GAAP financial measures including non-GAAP net income, non-GAAP diluted earnings per share and non-GAAP operating margin. Because these measures are used in InMode’s internal analysis of financial and operating performance, management believes that they provide greater transparency to investors of management’s view of InMode’s economic performance. Management also believes the presentation of these measures, when analyzed in conjunction with InMode’s GAAP operating results, allows investors to more effectively evaluate and compare the performance of InMode to that of its peers, although InMode’s presentation of its non-GAAP measures may not be comparable to other similarly-titled measures of other companies. Schedules reconciling each of these non-GAAP financial measures are provided as a supplement to this release.


Conference Call Information

Mr. Moshe MizrahyChairman and Chief Executive Officer, Dr. Michael Kreindel, co-founder and Chief Technology Officer, Mr. Yair Malca, Chief Financial Officer, Mr. Shakil Lakhani, President of North America, and Dr. Spero Theodorou, Chief Medical Officer, will host a conference call today, November 12, 2020, at 8:30 a.m. Eastern Time to discuss the third quarter 2020 financial results.

The Company encourages participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10148536/da3e5e2fe8. Callers will receive a unique dial-in upon registration, which enables immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.

For callers that opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call ten minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.

U.S. Toll-Free Dial-in Number: 1-866-777-2509


Israel Toll– Free Dial-in Number
: 1-80-921-2373

International Dial-in Number: 1-412-317-5413

At:

8:30 a.m. Eastern Time

5:30 a.m. Pacific Time

3:30 p.m. Israel Time

The conference call will also be webcast live from a link on InMode’s website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available from November 12, 2020 at 12 p.m. Eastern Time to November 26, 2020 at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers:

Replay Dial-in U.S TOLL-FREE: 1-877-344-7529

Replay Dial-in Canada TOLL-FREE: 855-669-9658

Replay Dial-in TOLL/INTERNATIONAL: 1-412-317-0088

Replay Pin Number: 10148536

A replay will also be available for 90 days on InMode’s website at https://inmodemd.com/investors/.

About InMode

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio-frequency (“RF”) technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically-accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.

Forward-Looking Statements

The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode’s future financial or operating performance, including the future performance described above under the heading titled “2020 Guidance.” Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “would” and similar expressions that concern our expectations, strategy plans or intentions. Forward-looking statements are based on management’s current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, including with respect to the impact of the COVID-19 global outbreak. As a result, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode’s Annual Report on Form F-20 filed with the Securities and Exchange Commission on February 18, 2020, risk factors relating to the COVID-19 global outbreak and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

 

Company Contact:

Yair Malca

Chief Financial Officer

Phone: (949) 305-0108

Email: [email protected]

Investor Relations Contact:

Miri Segal

MS-IR LLC

Phone: (917) 607-8654

Email: [email protected]

 

 

 


INMODE LTD.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(U.S. dollars in thousands, except for per share data)

(Unaudited)


Three months ended


September 30,


Nine months ended


September 30,


2020


2019


2020


2019


REVENUES

59,714

40,010

130,920

109,359


COST OF REVENUES

9,395

5,047

20,274

14,193


GROSS PROFIT


50,319


34,963


110,646


95,166


OPERATING EXPENSES:

Research and development

1,959

1,329

7,207

4,112

Sales and marketing

23,758

16,726

61,293

46,721

General and administrative

1,309

927

4,745

2,693


TOTAL OPERATING EXPENSES

27,026

18,982

73,245

53,526


INCOME FROM OPERATIONS


23,293


15,981


37,401


41,640

Finance income, net

798

479

2,063

1,264


INCOME BEFORE TAXES


24,091


16,460


39,464


42,904


INCOME TAXES

207

267

509

718


NET INCOME


23,884


16,193


38,955


42,186

Add: Loss (net income) attributable to non-controlling interests

11

(7)

(39)

(79)


NET INCOME ATTRIBUTABLE TO INMODE LTD.


23,895


16,186


38,916


42,107


NET INCOME PER SHARE:

Basic

0.65

0.53

1.09

1.50

Diluted

0.57

0.42

0.93

1.15


WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF NET INCOME PER SHARE

Basic

36,697

30,297

35,542

28,031

Diluted

42,082

39,004

41,894

36,654

 

 

 


INMODE LTD.

CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands, except for per share data)

(Unaudited)


September 30,


2020


December 31,


2019


Assets


CURRENT ASSETS:

Cash and cash equivalents

68,835

44,727

Marketable securities

122,046

120,144

Short-term bank deposits

43,436

28,491

Accounts receivable, net of allowance for doubtful accounts

16,164

6,628

Other receivables

4,790

3,810

Inventories

14,871

9,408


TOTAL CURRENT ASSETS

270,142

213,208


NON-CURRENT ASSETS:

Accounts receivable

455

374

Deferred income taxes, net

606

1,899

Operating lease right-of-use assets

1,282

1,369

Property and equipment, net

1,056

935

Other investments

600

600


TOTAL NON-CURRENT ASSETS

3,999

5,177


TOTAL ASSETS

274,141

218,385


Liabilities and shareholders’ equity


CURRENT LIABILITIES:

Accounts payable

4,283

3,702

Contract liabilities

15,671

15,587

Other liabilities

17,572

13,205


TOTAL CURRENT LIABILITIES

37,526

32,494


NON-CURRENT LIABILITIES:

Contract liabilities

2,069

3,813

Other liabilities

1,969

1,494

Operating lease liabilities

519

744

Deferred income taxes, net

32

37


TOTAL NON-CURRENT LIABILITIES

4,589

6,088


TOTAL LIABILITIES

42,115

38,582


TOTAL SHAREHOLDERS’ EQUITY

232,026

179,803


TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

274,141

218,385

 

 

 


INMODE LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(U.S. dollars in thousands, except for per share data)

(Unaudited)


Three months ended
September 30,


Nine months ended
September 30,


2020


2019


2020


2019


CASH FLOWS FROM OPERATING ACTIVITIES:

Net income

23,884

16,193

38,955

42,186

Adjustments required to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

108

77

307

214

Share-based compensation expenses

2,404

385

9,614

1,199

Allowance for doubtful accounts

55

466

133

Loss on marketable securities, net

11

2

Finance income, net

(279)

(86)

(11)

(395)

Deferred income taxes, net

347

(68)

1,173

(211)

Changes in operating assets and liabilities:

Increase in accounts receivable

(7,628)

(2,324)

(10,083)

(597)

Decrease (increase) in other receivables

537

(1,814)

(960)

(650)

Decrease (increase) in inventories

1,356

(879)

(5,463)

(1,532)

Increase in accounts payable

257

689

581

759

Increase in other liabilities

4,187

2,402

4,717

2,418

Increase (decrease) in contract liabilities

5,010

(1,115)

(1,660)

1,263

Decrease in accrued contingencies

(10,000)

Net cash provided by operating activities

30,194

13,515

37,638

34,787


CASH FLOWS FROM INVESTING ACTIVITIES:

Investment in short-term deposit

(18,090)

(17,220)

(49,699)

(34,310)

Proceeds from short-term deposit

6,720

8,500

34,810

18,500

Purchase of fixed assets

(103)

(54)

(428)

(518)

Purchase of marketable securities

(41,085)

(68,282)

(119,394)

(82,621)

Proceeds from sale of marketable securities

25,500

13,500

117,786

18,103

Net cash (used in) investing activities

(27,058)

(63,556)

(16,925)

(80,846)


CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from initial public offering of ordinary shares, net of offering costs

69,784

69,784

Exercise of options

698

178

3,248

315

Net cash provided by financing activities

698

69,962

3,248

70,099


EFFECT OF EXCHANGE RATE CHANGES ON CASH

234

(93)

147

(56)


NET INCREASE IN CASH AND CASH EQUIVALENTS

4,068

19,828

24,108

23,984


CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD

64,767

28,877

44,727

24,721


CASH AND CASH EQUIVALENTS AT END OF PERIOD

68,835

48,705

68,835

48,705

 

 

 


INMODE LTD.

CONDENSED CONSOLIDATED FINANCIAL HIGHLIGHTS

(U.S. dollars in thousands, except for per share data)

(Unaudited)


Three months ended
September 30,


Nine months ended
September 30,


2020


2019


2020


2019


Revenues by Geography:

United States

40,880

31,007

95,763

87,813

International

18,834

9,003

35,157

21,546


Total Net Revenue

59,714

40,010

130,920

109,359

U.S. as percentage of total revenue

68%

77%

73%

80%

 

 

 


INMODE LTD.

RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF

INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(U.S. dollars in thousands, except for per share data)

(Unaudited)


Three months ended 


September 30, 2020


Three months ended


September 30, 2019


GAAP


Share Based
Compensation


Non-GAAP


GAAP


Share Based
Compensation


Non-GAAP


REVENUES

59,714

59,714

40,010

40,010


COST OF REVENUES

9,395

(155)

9,240

5,047

(21)

5,026


GROSS PROFIT

50,319

155

50,474

34,963

21

34,984


OPERATING EXPENSES:

Research and development

1,959

(124)

1,835

1,329

(58)

1,271

Sales and marketing

23,758

(1,974)

21,784

16,726

(270)

16,456

General and administrative

1,309

(151)

1,158

927

(36)

891


TOTAL OPERATING
EXPENSES

27,026

(2,249)

24,777

18,982

(364)

18,618


INCOME FROM OPERATIONS

23,293

2,404

25,697

15,981

385

16,366

Finance income, net

798

798

479

479


INCOME BEFORE TAXES

24,091

2,404

26,495

16,460

385

16,845


INCOME TAXES (TAX BENEFIT)

207

(339)

(132)

267

59

326


NET INCOME

23,884

2,743

26,627

16,193

326

16,519

Add: Loss (net income) attributable to non-controlling interests

 

 

11

11

 

 

(7)

 

 

 

 

(7)


NET INCOME ATTRIBUTABLE TO INMODE LTD.

23,895

2,743

26,638

 

16,186

326

16,512


NET INCOME PER
SHARE:

Basic

0.65

0.73

0.53

0.55

Diluted

0.57

0.63

0.42

0.42


WEIGHTED AVERAGE
NUMBER OF SHARES
OUTSTANDING USED IN
COMPUTATION OF NET
INCOME PER SHARE

Basic

36,697

36,697

30,297

30,297

Diluted

42,082

42,289

39,004

39,047

 

 

 


INMODE LTD.

RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF

INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(U.S. dollars in thousands, except for per share data)

(Unaudited)


Nine months ended September 30, 2020


Nine months ended September 30, 2019


GAAP


Share Based
Compensation


Non-GAAP


GAAP


Share Based
Compensation


Non-GAAP


REVENUES

130,920

130,920

109,359

109,359


COST OF REVENUES

20,274

(380)

19,894

14,193

(62)

14,131


GROSS PROFIT

110,646

380

111,026

95,166

62

95,228


OPERATING EXPENSES:

Research and development

7,207

(2,132)

5,075

4,112

(166)

3,946

Sales and marketing

61,293

(6,569)

54,724

46,721

(887)

45,834

General and administrative

4,745

(533)

4,212

2,693

(84)

2,609


TOTAL OPERATING
EXPENSES

73,245

(9,234)

64,011

53,526

(1,137)

52,389


INCOME FROM OPERATIONS

37,401

9,614

47,015

41,640

1,199

42,839

Finance income, net

2,063

2,063

1,264

1,264


INCOME BEFORE TAXES

39,464

9,614

49,078

42,904

1,199

44,103


INCOME TAXES (TAX BENEFIT)

509

(763)

(254)

718

227

945


NET INCOME

38,955

10,377

49,332

42,186

972

43,158

Add: Loss (net income) attributable to non-controlling interests

(39)

(39)

(79)

(79)


NET INCOME ATTRIBUTABLE TO INMODE LTD.

38,916

10,377

49,293

42,107

972

43,079


NET INCOME PER
SHARE:

Basic

1.09

1.39

1.50

1.53

Diluted

0.93

1.17

1.15

1.17


WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF NET INCOME PER SHARE

Basic

35,542

35,542

28,031

28,031

Diluted

41,894

42,061

36,654

36,707

 

Cision View original content:http://www.prnewswire.com/news-releases/inmode-reports-record-third-quarter-2020-financial-results-quarterly-revenues-of-59-7-million-represent-49-year-over-year-growth-gaap-and-non-gaap-diluted-earnings-per-share-of-0-57-and-0-63–301171845.html

SOURCE InMode Ltd.

HOOKIPA Pharma Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

NEW YORK and VIENNA, Austria, Nov. 12, 2020 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reports its financial results for the third quarter ended September 30, 2020 and provides a corporate update.

“The third quarter saw continued advancement and validation of our clinical development programs, with a focus on our oncology pipeline of replicating arenavirus-based therapeutic candidates,” commented Joern Aldag, Chief Executive Officer of HOOKIPA. “We continue to gain momentum as we expanded our ongoing Phase 1/2 HPV trial to explore HB-202/HB-201 as an alternating vector therapy with the first patient dosed with HB-202. We are also pleased that preclinical immunogenicity data from HB-201, our lead oncology candidate, was recognized in OncoImmunology, further demonstrating the potential of our arenavirus-based therapies to combat cancer. Additionally, I am proud that Professor Jean-Charles Soria, a globally recognized scientist and oncologist, who is General Director of Gustave Roussy, the leading European Cancer Center, joined our Board of Directors. His expertise will enhance our efforts as we seek to advance new, much needed cancer therapies.”

R&D Pipeline Update and Clinical Progress

HB-101, lead product candidate in infectious diseases
HOOKIPA’s prophylactic Cytomegalovirus (CMV) vaccine candidate, HB‑101, is in a randomized, double‑blinded Phase 2 clinical trial in patients awaiting kidney transplantation who are at risk for CMV-associated complications post-transplant. In June 2020, HOOKIPA announced positive Phase 2 interim data on the trial’s primary endpoints: safety, and B cell and T cell immunogenicity. The interim data demonstrated that HB‑101 was well tolerated, with a lower rate of adverse events in patients with end-stage kidney disease than in the Phase 1 healthy volunteer trial. Patients who received the sponsor recommended three doses of HB‑101 showed comparable immunogenicity levels to those measured in the Phase 1 healthy volunteer trial. HOOKIPA continues to accrue patients and plans to report preliminary efficacy and updated safety and immunogenicity data by the end of 2020.

HB-201 and HB-202, lead programs in immuno-oncology treating Human Papillomavirus-positive cancers
HOOKIPA’s lead oncology product candidates, HB‑201 and HB‑202, are in development for the treatment of Human Papillomavirus 16‑positive (HPV16+) cancers. In December 2019, HOOKIPA initiated the Phase 1/2 clinical trial with endpoints of safety, immunogenicity and efficacy. The open label, dose escalating Phase 1/2 clinical trial in HPV16+ cancers is currently evaluating HB-201 alone and subsequently in combination with an approved checkpoint inhibitor. Accrual of patients for the first and the second dose levels at a three-week dosing frequency has been completed without safety concerns. Additional dose schedules and levels are being investigated to identify the recommended Phase 2 dose. HOOKIPA expects to report preliminary safety and efficacy data in late 2020 or early 2021.

A peer reviewed article in OncoImmunology issued in September 2020 recognized that HB-201 preclinical results demonstrated high immunogenicity. The paper verified that systemically administered HB-201 leads to dose-dependent induction of a robust, systemic cytotoxic T cell response directed against HPV16 proteins, tumor infiltration of HPV16 specific cytotoxic T cells, as well as significantly delayed tumor growth or complete tumor clearance accompanied with prolonged survival.

In October 2020, HOOKIPA announced the dosing of the first patient with HB-202. HB-202 is part of a sequential alternating vector regimen of HB-202/HB-201 for the treatment of HPV16+ cancers in the ongoing HB-201 Phase 1/2 trial. In pre-clinical studies, alternating administration of HB-202 and HB-201 resulted in a ten-fold increase in immune response and better disease control than either compound alone. The Company expects to provide interim safety, dose escalation, and efficacy data on the HB-202/HB-201 arm of the ongoing Phase 1/2 study in mid-2021.

Strategic Collaborations


Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines
Since the start of the collaboration in 2018, HOOKIPA has received $21.0 million in upfront and milestone payments from Gilead for the delivery of research vectors and for advancing the programs towards clinical trials, including a milestone payment of $4.0 million, which the Company received in early 2020. Based on preclinical data generated to date, Gilead committed to advancing the HBV and HIV vectors toward development. To enable the development activities and expanded research programs, Gilead agreed to reserve manufacturing capacity and increase reimbursement planned for the Company’s expanded resources allocated to the Gilead collaboration.

Others

In October 2020, Professor Jean-Charles Soria, M.D., Ph.D., was appointed to HOOKIPA’s Board of Directors. Jean-Charles Soria is Professor of Medicine and Medical Oncology at the University of Paris-Saclay and currently serves as General Director of the Gustave Roussy Cancer Center, one of the world’s leading cancer research institutes. 

COVID-19

HOOKIPA continues to monitor the COVID-19 pandemic closely and adapt to COVID-19 measures and recommendations issued by the U.S. and Austrian governments. For disclosures of risks and uncertainties resulting from the COVID-19 disease outbreak, including the impact on the enrollment of patients and timing of clinical results, see HOOKIPA’s quarterly reports on Form 10-Q for the quarters ended June 30, 2020 and September 30, 2020.

Third Quarter 2020 Financial Results

Cash Position:

HOOKIPA’s cash, cash equivalents and restricted cash as of September 30, 2020 was $82.3 million compared to $113.6 million as of December 31, 2019. The decrease was primarily attributable to cash used in operating activities.

Revenue was $4.0 million for the three months ended September 30, 2020 compared to $2.0 million for the three months ended September 30, 2019. The increase was primarily due to higher cost reimbursements received under the collaboration agreement with Gilead following the expansion of the collaboration in the first half of 2020 and the partial recognition of a milestone payment we received from Gilead in February 2020.

Research and Development Expenses:

HOOKIPA’s research and development expenses were $16.0 million for the three months ended September 30, 2020 compared to $11.0 million for the three months ended September 30, 2019. The primary drivers of the increase compared to 2019 were an increase in clinical trial expenses of $2.7 million and an increase in internal research and development expenses of $2.3 million.

General and Administrative Expenses:

General and administrative expenses amounted to $4.4 million for the three months ended September 30, 2020 compared to $4.6 million for the three months ended September 30, 2019. The decrease was primarily due to a decrease in personnel-related expenses of $0.1 million, a decrease in professional and consulting fees of $0.5 million, partially offset by an increase of other general and administrative expenses of $0.4 million.

Net Loss:

HOOKIPA’s net loss was $13.6 million for the three months ended September 30, 2020 compared to a net loss of $11.4 million for the three months ended September 30, 2019.

About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system.

HOOKIPA’s proprietary arenavirus-based technologies, non-replicating (VaxWave®) and replicating (TheraT®), induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.

HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.

In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial.

Find out more about HOOKIPA online at www.hookipapharma.com.

HOOKIPA Forward Looking Statements

Certain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises, the impact of COVID-19 on the enrollment of patients and timing of clinical results for HB-101 and other programs, and other matters that could affect the sufficiency of existing cash to fund operations and HOOKIPA’s ability to achieve the milestones under the agreement with Gilead. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA’s quarterly report on Form 10-Q for the quarter ended September 30, 2020 which is available on the Security and Exchange Commission’s website at www.sec.gov and HOOKIPA’s website at www.hookipapharma.com. 

Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.

HOOKIPA Pharma Inc.

Consolidated Statements of Operations (Unaudited)

(In thousands, except share and per share data)

    Three months ended September 30,    Nine months ended September 30, 
    2020     2019     2020     2019  
Revenue from collaboration and licensing   $ 4,040     $ 2,038     $ 14,421     $ 8,324  
Operating expenses:                        
Research and development     (16,009 )     (11,025 )     (39,099 )     (35,133 )
General and administrative     (4,437 )     (4,589 )     (13,413 )     (11,051 )
Total operating expenses     (20,446 )     (15,614 )     (52,512 )     (46,184 )
Loss from operations     (16,406 )     (13,576 )     (38,091 )     (37,860 )
Total interest, other income and taxes, net     2,817       2,191       6,483       5,067  
Net loss   $ (13,589 )   $ (11,385 )   $ (31,608 )   $ (32,793 )
Net loss per share — basic and diluted     (0.53 )     (0.45 )     (1.23 )     (2.14 )
Weighted average common shares outstanding — basic and diluted     25,659,504       25,408,488       25,645,827       15,308,071  

Condensed Balance Sheets (Unaudited)

(In thousands)

             
       As of      As of
    September 30,    December 31, 
    2020   2019
Cash, cash equivalents and restricted cash   $ 82,259   $ 113,575
Total assets     121,272     143,745
Total liabilities     29,092     25,846
Total stockholders’ equity     92,180     117,899

For further information, please contact:  
Media Investors
Nina Waibel Matt Beck
Senior Director – Communications Executive Director – Investor Relations
[email protected] [email protected]
   
Media enquiries  
Instinctif Partners  
[email protected]  
+44 (0)20 7457 2020  

Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview


On
T
rack to
Complete GMP Batch Runs in Mid-2021 to C
onfirm
C
omparability
B
etween TARA-002 and OK-432



Expect to
I
nitiate Phase 1
T
rial for TARA-002 in
P
atients with
N
on-
M
uscle
I
nvasive
B
ladder
C
ancer in 2021



Requested
M
eeting with FDA to
D
iscuss
P
ath
F
orward for TARA-002 in Lymphatic Malformations



Strong
C
ash
P
osition of $166M as of September 30, 2020

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the third quarter ended September 30, 2020.

“The third quarter marked a highly productive time for the Company, notably with the Food and Drug Administration’s (FDA) confirmation of initial comparability between TARA-002 and OK-432, and separately the Company’s identification of an acceptable development path for TARA-002 in non-muscle invasive bladder cancer (NMIBC), an oncology indication with high unmet need,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “We believe TARA-002 has the potential to serve as a much needed intervention for NMIBC patients lacking alternative therapeutic options, and we look forward to the expected commencement of our clinical program in NMIBC in 2021. Finally, we have requested a meeting with the FDA Division of Vaccines and Related Products, the review division which the Investigational New Drug (IND) application was initially opened by the University of Iowa, to discuss a potential Biological License Application (BLA) filing for TARA-002 in lymphatic malformations (LMs).”

Recent Highlights

TARA-002

In September 2020, Protara announced the following updates for the TARA-002 program:

  • FDA Confirmation of
    Initial
    Comparability
    Between TARA-002 and OK-432. Following a pre-IND engagement with the Office of Tissues and Advanced Therapies (OTAT) division of the Center for Biologics Evaluation and Research (CBER), the FDA agreed that Protara has successfully demonstrated initial manufacturing comparability between TARA-002 and OK-432 and that the in-process and release protocols employed by Protara to demonstrate initial comparability are appropriate to utilize for GMP-Scale comparability testing. Good Manufacturing Practice (GMP) scale-up is currently in process and the Company expects to complete three such large-scale batch runs to confirm comparability in mid-2021.

  • Clinical Development Path in NMIBC. The Company reached alignment with the FDA on a proposed clinical development plan to evaluate TARA-002 in patients with NMIBC. Advancement into the clinic will be supported by existing and ongoing non-clinical studies as well as historical clinical safety and efficacy data for OK-432. Subject to the successful completion of select non-clinical studies to characterize local toxicity of intravesical administration of TARA-002, as well as acceptance of an IND filing, the Company plans to commence a Phase 1 study in 2021 to assess the safety and tolerability of TARA-002 in patients with NMIBC, including patients with carcinoma in situ (CIS), with results expected in 2022.

  • Regulatory Path in LMs. Protara has requested a meeting with the FDA Division of Vaccines and Related Products Applications to discuss the regulatory path for TARA-002 in LMs. The Company plans to utilize the robust dataset for OK-432 in LMs to support a BLA filing for TARA-002 in LMs.

IV Choline Chloride

  • Prevalence Study
    Underway
    to Assess
    Incidence of Liver Disease in Patients Dependent on Parenteral Nutrition
    (PN)
    . The Company recently commenced a prevalence study to assess the incidence of liver disease in patients dependent on PN in the home care setting. The Company believes the study will enhance its understanding of the population of patients who may potentially benefit from IV Choline Chloride, its investigational phospholipid substrate replacement therapy currently in development for the treatment of patients receiving PN who have intestinal failure-associated liver disease (IFALD).

Corporate Update

  • Raised
    $
    1
    5
    1
    Million
    in Concurrent Public Offerings. Protara recently announced the closing of concurrent but separate underwritten public offerings of 4,600,000 shares of its common stock, at a public offering price of $16.87 per share, and 4,148 shares of non-voting Series 1 Convertible Preferred Stock, at a public offering price of $16,873.54 per share. In addition, the underwriters exercised their overallotment option in full to purchase an additional 690,000 shares of common stock at a public offering price of $16.87. Aggregate net proceeds to Protara were approximately $151 million, after deducting underwriting discounts and offering expenses.

Third
Quarter 2020 Results from Operatio
ns

  • As of September 30, 2020, cash and restricted cash were $166.0 million.
  • Protara reported a net loss of $8.0 million for the third quarter of 2020 as compared to a net loss of $2.4 million for the three months ended September 30, 2019. The third quarter of 2020 included approximately $2.8 million of stock-based compensation expense.
  • Research and Development expenses were $2.8 million for the third quarter of 2020, an increase of $1.7 million as compared to the three months ended September 30, 2019. The increase was primarily due to an increase of (i) $0.6 million in personnel and related costs, (ii) $0.8 million in chemistry manufacturing and controls (CMC) expenses and (iii) $0.3 million in regulatory expenses.
  • General and Administrative expenses were $5.3 million for the third quarter of 2020, which represented an increase of $4.0 million as compared to the three months ended September 30, 2019.  The increase was primarily related to an increase of (i) $2.6 million in stock-based compensation expense, (ii) $0.6 million in insurance expense and (iii) $0.7 million in personnel and related costs.

A Form 10-Q containing the full financial statements was filed this morning and is available for viewing on Protara’s website at www.protaratx.com or www.sec.gov.

About TARA-002

TARA-002 is an investigational cell therapy in development for the treatment of lymphatic malformations (LMs) and non-muscle invasive bladder cancer (NMIBC). TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan and Taiwan by Chugai Pharmaceutical Co., Ltd. Protara successfully demonstrated initial manufacturing comparability between TARA-002 and OK-432.

When TARA-002 is administered, it is hypothesized that innate and adaptive immune cells within the cyst or tumor are activated and produce a strong immune cascade. Neutrophils, monocytes and lymphocytes infiltrate the abnormal cells and various cytokines, including interleukins IL-6, IL-8, IL-12, interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, and vascular endothelial growth factor (VEGF) are secreted by immune cells to induce a strong local inflammatory reaction and destroy the abnormal cells. TARA-002 has been granted Rare Pediatric Disease Designation by the U.S. Food and Drug Administration for the LMs indication.

About
Non-Muscle Invasive Bladder Cancer

Bladder cancer is the 6th most common cancer in the United States, with non-muscle invasive bladder cancer (NMIBC) representing approximately 80% of bladder cancer diagnoses. Approximately 65,000 patients are diagnosed with NMIBC in the United States each year. NMIBC is cancer found in the tissue that lines the inner surface of the bladder that has not spread into the bladder muscle. The current standard of care for high-grade NMIBC includes intravesical Bacillus Calmette-Guerin (BCG), which has been the subject of multiple global supply shortages in the past decade.

About
Lymphatic Malformations

Lymphatic malformations (LMs) are rare, congenital malformations of lymphatic vessels resulting in the failure of these structures to connect or drain into the venous system. Most LMs are present in the head and neck region and are diagnosed in early childhood during the period of active lymphatic growth, with more than 50% detected at birth and 90% diagnosed before the age of 2 years. The most common morbidities and serious manifestations of the disease include compression of the upper aerodigestive tract, including airway obstruction requiring intubation and possible tracheostomy dependence; intralesional bleeding; impingement on critical structures, including nerves, vessels, lymphatics; recurrent infection, and cosmetic and other functional disabilities.

About IV Choline Chloride and Intestinal Failure-associated Liver Disease (IFALD)

IV Choline Chloride is an investigational, intravenous (IV) phospholipid substrate replacement therapy initially in development for patients receiving parenteral nutrition (PN) who have IFALD. Choline is a known important substrate for phospholipids that are critical for healthy liver function. Because PN patients cannot sufficiently absorb adequate levels of choline and no available PN formulations contain sufficient amounts of choline to correct this deficiency, PN patients often experience a prolonged progression to hepatic failure and death, with the only known intervention being a dual small bowel/liver transplant. If approved, IV Choline Chloride would be the first approved therapy for IFALD. It has been granted Orphan Drug Designations (ODDs) by the FDA for the treatment of IFALD and the prevention of choline deficiency in PN patients.

About Protara
 
Therapeutics, Inc.

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding Protara’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Protara’s business strategy, Protara’s development plans for its product candidates , including its plans regarding the timing or outcome of existing or future non-clinical studies and clinical trials, Protara’s expectations regarding interactions or upcoming filings with the FDA, statements regarding the anticipated safety or efficacy of Protara’s product candidates and, Protara’s financial footing. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include: risks that Protara’s sales, revenue, expense and other financial guidance may not be as expected, as well as risks and uncertainties associated with: Protara’s development programs, including the initiation and completion of non-clinical studies and clinical trials and the timing of required filings with the FDA and other regulatory agencies; the impact of the COVID-19 pandemic on Protara’s business and the global economy; general market conditions; changes in the competitive landscape; changes in Protara’s strategic and commercial plans; Protara’s ability to obtain sufficient financing to fund its strategic plans and commercialization efforts; having to use cash in ways or on timing other than expected; the impact of market volatility on cash reserves; the loss of key members of management; and the risks and uncertainties associated with Protara’s business and financial condition in general, including the risks and uncertainties described more fully under the caption “Risk Factors” and elsewhere in Protara’s filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Protara undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.

Company Contact:

Blaine Davis
Protara Therapeutics
[email protected]
646-844-0337

 PROTARA THERAPEUTICS, INC.  
CONDENSED CONSOLIDATED BALANCE SHEETS  
           
    As of  
    September 30, 2020   December 31, 2019  
    (unaudited)      
Assets          
Current assets:          
Cash and cash equivalents   $ 165,904,797     $ 564,124    
Restricted cash     50,000          
Deferred offering costs           121,712    
Prepaid expenses and other current assets     1,160,257       78,057    
Total current assets     167,115,054       763,893    
           
Non-current assets:          
Property and equipment, net     760,548       458,591    
Goodwill     29,367,213          
Other assets     1,664,442          
Total assets   $ 198,907,257     $ 1,222,484    
           
Liabilities and Stockholders’ Equity (Deficit)          
Current liabilities:             
Accounts payable   $ 1,912,553     $ 715,653    
Accrued expenses     1,569,348       2,634,790    
Short-term debt     370,793          
Right-of-use liability, current     34,079          
      Total current liabilities     3,886,773       3,350,443    
           
Non-current liabilities:          
Right-of-use liability, long-term     394,721          
      Total liabilities     4,281,494       3,350,443    
           
Commitments and Contingencies (Note 6)          
           
Stockholders’ Equity (Deficit)          
Preferred Stock, $0.001 par value, authorized 10,000,000 shares:          
Series 1 Convertible Preferred Stock, 8,028 and 0 shares authorized at September 30, 2020          
and December 31, 2019, respectively, 8,027 and 0 shares issued and outstanding as of          
September 30, 2020 and December 31, 2019, respectively.     8          
Common Stock, $0.001 par value, authorized 100,000,000 shares:          
Common Stock, 10,521,840 and 2,627,533 common shares issued and outstanding as of          
September 30, 2020 and December 31, 2019, respectively.     10,522       2,628    
Additional Paid in Capital     232,567,265       10,651,073    
Accumulated Deficit     (37,952,032 )     (12,781,660 )  
Total Stockholders’ Equity (Deficit)     194,625,763       (2,127,959 )  
      Total Liabilities and Stockholders’ Equity (Deficit)   $ 198,907,257     $ 1,222,484    
           
PROTARA THERAPEUTICS, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
(unaudited)  
                   
    For the Three Months Ended September 30,   For the Nine Months Ended September 30,  
      2020       2019       2020       2019    
                   
Operating expense:                  
Research & development   $ 2,796,214     $ 1,098,617     $ 8,330,727     $ 3,163,179    
General & administrative     5,265,965       1,255,466       17,156,952       2,147,635    
      Total operating expenses     8,062,179       2,354,083       25,487,679       5,310,814    
                   
      Operating loss     (8,062,179 )     (2,354,083 )     (25,487,679 )     (5,310,814 )  
                   
Other income, net                  
Interest income, net     (92,094 )           (317,307 )        
Total other income, net     (92,094 )           (317,307 )        
                   
Net Loss   $ (7,970,085 )   $ (2,354,083 )   $ (25,170,372 )   $ (5,310,814 )  
                   
Weighted Average Shares Outstanding, basic and diluted   6,324,295       2,564,429       5,910,849       2,560,444    
                   
Net loss per share, basic and diluted   $ (1.26 )   $ (0.92 )   $ (4.26 )   $ (2.07 )